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SUMMARY 
 
Gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
(MALT lymphoma) represents a distinct class of extranodal lymphoma that evolves against a 
background of chronic inflammation induced by persistent infection with the bacterium 
Helicobacter pylori. In its early stages, MALT lymphoma is an antigen-dependent disease 
characterised by an indolent clinical course and in most cases is treatable by antibiotic 
eradication therapy alone. Low grade MALT lymphomas can eventually undergo high grade 
transformation to a more aggressive counterpart termed gastric diffuse large B-cell 
lymphoma (gDLBCL). At this stage the lymphomas grow autonomously and are refractory to 
Helicobacter eradication therapy. Little is known about the molecular mechanisms governing 
the development of low grade MALT lymphoma and its ultimate progression to gDLBCL. 
To improve our current understanding of the molecular pathogenesis of MALT lymphoma, a 
multidimensional approach was taken to investigate various aspects of this disease during the 
course of my PhD thesis.  
 
Although a variety of circumstantial evidence has implicated an important role for 
antigen in MALT lymphomagenesis, the identity of such ligands recognised by the tumour 
cells remain unclear. To address this issue of antigen-receptor specificity, enzyme 
immunoassays were employed to systematically analyse the antigen binding profile of a 
comprehensive panel of human and murine recombinant MALT lymphoma-derived 
antibodies. The majority of tumour derived immunoglobulins were found to exhibit a broad 
reactivity profile in line with the definition of polyreactivity. In addition, using the BALB/c 
mouse model of Helicobacter-induced gastric MALT lymphoma, we demonstrated that 
explanted tumour cells proliferated in response to a variety of cognate antigens recognised by 
their polyreactive B-cell receptor. Our results therefore suggest that MALT lymphoma 
development may be facilitated by an array of local self- and foreign antigens, providing 
direct antigenic stimulation of the tumour cells via their B-cell receptor. 
 
A characteristic feature of gastric MALT lymphomas is that they are typically 
infiltrated by large numbers of T-helper cells producing interleukin-4 (IL4) and other T-
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helper cell type 2 cytokines. Therefore, an additional aim of this study was to elucidate the 
pathogenic role of the tumour-infiltrating T-cell population. Tumour cell proliferation was 
strongly enhanced by the presence of intratumoural CD4+ T cells in a CD40/CD40L-
independent manner. Another key finding was that a substantial fraction of tumour-
infiltrating CD4+ T cells were functional CD25+FoxP3+ regulatory T (Treg) cells. These cells 
were found to be recruited by the tumour cells themselves through secretion of the Treg-
attracting chemokines CCL17 and CCL22. Interestingly, the depletion of CD25+ T cells was 
as efficient as CD4+ T-cell depletion in blocking tumour growth ex vivo and in vivo. Judging 
from our data, we propose that MALT lymphoma cells require at least two independent 
signals for proliferation. One signal is received by the functional surface-bound polyreactive 
immunoglobulin, while the other signal is delivered by tumour-infiltrating T cells, in 
particular by Tregs, which are likely to play a direct role in stimulating tumour growth.  
 
To date, MALT lymphoma research has largely focused on altered expression of 
protein coding genes. However, recent evidence suggests that alterations of non-coding 
RNA, particularly microRNA (miRNA), also contribute to tumourigenesis. Using a genome-
wide microarray-based approach, we defined the unique miRNA expression signature 
associated with the development and progression of this disease. A special focus was first 
laid upon miR-203 and its putative tumour suppressive function during the progression from 
reactive Helicobacter-specific gastritis to MALT lymphoma. We identified miR-203 to be 
significantly downregulated in MALT lymphoma tissue due to hypermethylation of the miR-
203 locus. The restoration of miR-203 expression in primary MALT lymphoma cells 
repressed the recently identified miR-203 target, ABL1, and blocked tumour cell 
proliferation. Finally, pharmacological inhibition of ABL1 activity by imatinib blocked 
MALT lymphoma cell proliferation ex vivo and effectively eradicated tumours in vivo. 
Collectively, our observations suggest that ABL1 plays an important role in MALT 
lymphoma cell biology and support a novel potential application of imatinib in the treatment 
of MALT lymphoma. 
 
Our genome-wide survey further revealed a characteristic set of MYC-repressed 
miRNAs to be specifically downregulated in human gDLBCL compared to MALT 
SUMMARY 
  6 
 
lymphoma and gastritis. Aberrant MYC expression indeed correlated with high grade 
transformation as evident from our tissue microarray analysis. The re-expression of a panel 
of selected MYC-associated miRNAs significantly reduced the proliferation of DLBCL cells. 
In particular, miR-34a was found to represent the most potent tumour suppressor in DLBCL 
cell lines. We could further attribute the tumour suppressive effects of miR-34a to 
dysregulation of its target FOXP1. Accordingly, FOXP1 overexpression was found to be 
strongly associated with gDLBCL and the transient knockdown of FOXP1 in DLBCL cell 
lines significantly impaired the proliferation of the tumour cells. Taken together, our findings 
elucidate a novel mechanism linking the aberrant expression of MYC and concomitant 
repression of miR-34a to FOXP1 deregulation in high grade transformation of MALT 
lymphoma.  
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ZUSAMMENFASSUNG 
Gastrische Marginalzonen-B-Zell Lymphome des Schleimhaut-assoziierten 
lymphatischen Gewebes (MALT Lymphome) stellen eine eigene Klasse der extranodalen 
Lymphome dar, die sich nach chronischer Magenentzündung infolge persistierender 
Infektion mit dem bakteriellen Humanpathogen Helicobacter pylori bilden. Im Frühstadium 
zeichnen sich MALT Lymphome durch einen relativ indolenten klinischen Verlauf aus; in 
der Mehrheit der Fälle können die früh diagnostizierten Lymphome aufgrund ihrer 
Abhängigkeit von der Helicobacter-Infektion durch eine antibiotische Therapie geheilt 
werden. Niedrigmaligne MALT Lymphome können sich potentiell in hochmaligne, 
aggressive Lymphome entwickeln, welche dann als „grosszelliges B-Zelllymphom des 
Magens“ (gDLBCL) bezeichnet werden. In diesem Stadium sind die Lymphome 
antigenunabnängig und lassen sich durch Helicobacter-Eradikation nicht behandeln. Über die 
molekularen Mechanismen der hochgradigen Transformation des MALT Lymphoms zu 
gDLBCL ist bisher nur wenig bekannt. Um den jetzigen Wissensstand über die molekulare 
Pathogenese der MALT Lymphome zu verbessern, haben wir während meiner Dissertation 
einen multidimensionalen Ansatz verfolgt, welcher diverse Aspekte dieser Krankheit 
beleuchtet hat. 
  Obwohl eine Vielzahl von Resultaten zeigen, dass Antigene eine entscheidenden 
Rolle bei der Entwicklung von MALT Lymphomen spielen, war bisher unklar, ob diese von 
oberflächenständigen Immunglobulinen der Tumorzellen erkannt werden können. Um die 
Antigen-Spezifität der Tumorimmunglobuline zu untersuchen, haben wir ELISA-
Experimente zur systematischen Analyse des Antigenbindungsprofils durchgeführt. Hierzu 
haben wir humane wie auch murine Antikörper untersucht, welche von MALT Lymphomen 
stammen. Die Mehrzahl dieser Immunoglobuline besitzt ein breites, „polyreaktives“ 
Reaktionsspektrum, d.h. sie reagieren jeweils mit einer Vielzahl von Antigenen. Zusätzlich 
konnten wir zeigen, dass explantierte Tumorzellen über ihren polyreaktiven B-Zell Rezeptor 
verschiedene Antigene erkennen und durch sie zur Proliferation angeregt werden können.  
Ein charakteristisches Merkmal der gastrischen MALT Lymphome ist, dass sie 
typischerweise durch eine grosse Anzahl von T-Helferzellen infiltriert werden, welche 
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Interleukin-4 und andere Th2 Zytokine produzieren. Demzufolge war es ein weiteres Ziel 
meiner Arbeit, die pathogene Rolle der tumorinfiltrierenden T-Zellen aufzuklären. Wir 
konnten zeigen, dass die Vermehrung der Tumorzellen durch die Gegenwart von 
eingewanderten CD4+ T-Zellen in Abhängigkeit von der CD40/CD40L Interaktion verstärkt 
wird. Eine weitere entscheidende Erkenntnis war, dass ein signifikanter Teil der tumor- 
infiltrierenden CD4+ T-Zellen aus funktionalen CD25+FoxP3+ regulatorischen T-Zellen 
(Treg) besteht. Diese Zellen wurden durch die Tumorzellen aktiv durch Sekretion der 
Chemokine CCL17 und CCL22 rekrutiert, welche Treg anlocken. Interessanterweise konnten 
wir beobachten, dass das Tumorwachstum ex vivo wie in vivo durch Depletion der CD25+ T- 
Zellen oder der CD4+ T-Zellen gehemmt werden konnte. Aus diesen Erkenntnissen 
schliessen wir, dass MALT Lymphome mindestens zwei Signale zur Proliferation benötigen.  
Eines dieser Signale wird durch die funktionalen polyreaktiven Immunoglobuline auf der 
Oberfläche übermittelt. Das andere Signal wird hingegen durch tumorinfiltrierende T-Zellen, 
insbesondere Treg, vermittelt, welche möglicherweise eine direkte Rolle bei der Stimulation 
des Tumorwachstums spielen. 
 In der MALT Lymphom-Forschung wurden bis heute überwiegend 
Expressionsveränderungen von proteinkodierenden Genen betrachtet, wobei neue 
Forschungsergebnisse zeigen, dass nicht-kodierende RNA, insbesondere microRNA 
(miRNA) in der Tumorentstehung eine entscheidende Rolle spielen können. Mit Hilfe eines 
microarraybasierten, genomweiten Ansatzes konnten wir miRNA-Expressionsmuster 
beschreiben, die mit der Entwicklung dieser Krankheit korrelieren. Ein Schwerpunkt lag 
dabei auf miR-203 und der tumorsuppressiven Funktion dieser miRNA bei der Progression 
von Helicobacter-abhängiger Gastritis zum MALT Lypmhom. Die Expression von miR-203 
war im MALT Lymphomgewebe durch Hypermethylierung des miR-203 Locus signifikant 
herunterreguliert. Die experimentelle Überexpression von miR-203 in primären MALT 
Lymphomzellen unterdrückt das kürzlich identifizierte Target ABL1 und hemmt die 
Proliferation der Tumorzellen. Zudem konnten wir zeigen, dass die Inhibition der ABL1-
Aktivität durch Imatinib die Vermehrung der MALT Lymphomzellen ex vivo hemmt und die 
Tumorentstehung im Tiermodell effizient unterdrückt. ABL1 scheint somit eine wichtige 
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Rolle bei der Entwicklung von MALT Lymphomen zu spielen; folglich kann Imatinib für die 
Behandlung von MALT Lymphompatienten in Betracht gezogen werden. 
Unsere Genomanalyse hat weiterhin gezeigt, dass eine bestimmte Gruppe von MYC- 
reprimierten miRNAs in humanen gDLBCL im Vergleich zu MALT Lymphomen und 
Gastritis herunterreguliert sind. Wie wir in Gewebearray-Analysen immunhistochemisch 
zeigen konnten, korreliert eine aberrante MYC-Expression tatsächlich mit der hochgradigen 
Transformation des MALT Lymphoms. In der Tat kann die Proliferation von DLBCL Zellen 
durch experimentelle Re-Expression der MYC-regulierten miRNAs deutlich reduziert 
werden. Die miR-34a hat dabei die stärksten tumorsuppressiven Eigenschaften in DLCBL 
Zelllinien gezeigt, welche wir auf eine Dysregulierung des miR-34a Targets FOXP1 zurück- 
führen konnten. Übereinstimmend mit diesen Resultaten haben wir eine Korrelation 
zwischen FOXP1 Überexpression und hochgradiger Transformation des MALT Lymphoms 
beobachtet; zudem hat ein transienter Knockdown von FOXP1 in DLBCL Zelllinien die 
Proliferation von Tumorzellen deutlich gehemmt. Unsere Ergebnisse stellen somit einen 
Zusammenhang her zwischen der Überexpression von MYC, der daraus resultierenden 
Repression von miR-34a und anderen MYC-reprimierten miRNAs,  und der Überexpression 
von FOXP1, welche mit der hochgradigen Transformation des MALT Lymphoms 
korrelieren und diese möglicherweise verursachen können. 
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1 INTRODUCTION 
 
1.1 The biology of gastric MALT lymphoma  
 In 1983, Isaacson and Wright first described a novel form of extranodal non-
Hodgkin’s B-cell lymphoma arising in mucosal organs with a distinct indolent clinical 
course.1 The term ‘MALT lymphoma’ was established owing to their observation that the 
histological features recapitulated those of the Peyer’s patch, a component of mucosa 
associated lymphoid tissue (MALT) found in the small intestines. It was not until 1994 that 
MALT lymphoma was officially recognised as a discrete entity in the group of marginal zone 
B-cell lymphomas by the Revised European-American Lymphoma (REAL) classification. In 
the current world health organisation (WHO) classification system, MALT lymphomas are 
grouped with splenic and nodal marginal-zone lymphomas based on the normal cell 
counterpart of these B-cell neoplasms (the marginal zone B-cell). Despite this common 
histological feature, MALT lymphoma differs from its nodal and splenic counterparts with 
respect to pathological and clinical behaviour.  
 
 MALT lymphomas arise in the context of pre-existing prolonged lymphoid 
proliferation in a wide variety of mucosal sites that are normally devoid of organised 
lymphoid tissue. The stomach is the most commonly affected organ (70% of cases), while 
other tumour sites include the lung (14%), ocular adnexa (12%), thyroid (4%) and small 
intestine (1%). The lymphoid tissue, from which the neoplastic B-cell clones emerge, is 
acquired in response to chronic infection or autoimmune disease and therefore exemplifies 
the close pathogenic link between chronic inflammation and tumour development. In the case 
of gastric lymphoma, persistent infection with the bacterium Helicobacter pylori is 
recognised as the etiological agent responsible for creating the chronic local inflammatory 
environment necessary for this type of lymphoma to develop.  
 
MALT lymphomas comprise 7-8 % of all B-cell lymphomas making them the third most 
common subtype, after diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.2 
Gastric MALT lymphoma represents the most frequent lymphoma of the gastrointestinal 
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tract accounting for least 50% of all gastric haematopoietic malignancies and up to 5% of all 
gastric neoplasms.3, 4 In the case of gastric MALT lymphoma, the disease is remarkably 
indolent and tends to remain localised to the stomach for long periods. The ten-year survival 
rate for gastric MALT lymphoma is close to 90% with a disease-free survival of 
approximately 70%.5, 6 However, MALT lymphomas can progress and transform into 
aggressive high grade tumours (gDLBCL), whereby the ten-year survival rate falls to 
approximately 42%.5  
 
1.1.1 Clinical and histopathological features  
The neoplastic B cells of MALT lymphoma share the cytological features and 
immunophenotype (CD20+, CD21+, CD35+, IgM+, IgD–) of marginal zone B cells.7 The 
tumour cells can resemble follicle-centre centrocytes (centrocyte-like cells) or small 
lymphocytes (monocytoid B cells) (Figure 1.1d, e). Scattered large (transformed) lymphoma 
cells (immunoblasts and centroblast-like cells) are also common. The infiltrate occurs in the 
marginal zone of reactive B-cell follicles and extends into the interfollicular region.8  
 
A characteristic feature of MALT lymphoma is the presence of lymphoepithelial 
lesions (LELs), defined by the invasion and destruction of individual mucosal glands or other 
epithelial structures by clusters of (usually three or more) neoplastic cells (Figure 1.1a, c). 
Plasma cell differentiation occurs in a third of all MALT lymphoma cases and tends to be 
maximal beneath the surface epithelium. Follicular colonisation is another phenomenon of 
MALT lymphoma and describes the extension of tumour cells into germinal centres (GCs) of 
non-malignant reactive B-cell follicles (Figure 1.1b).9 Several studies have reported that 
gastric MALT lymphomas are infiltrated by large numbers of T-helper cells expressing 
interleukin-4 (IL4) and other T-helper cell type 2 (Th2) cytokines (see section 1.1.4.2).10-12 
Histologic transformation of MALT lymphoma to gDLBCL is characterised by increased 
numbers of large blast cells that form confluent aggregates or sheets that can ultimately 
efface any residual preceding low grade tumour.13   
 
Diagnosis of gastric MALT lymphoma is made by morphologic analysis of 
endoscopic mucosal biopsy samples. Histologic grading of gastric biopsies is usually 
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performed according to a scoring system developed by Wotherspoon in 1993 (Table 1.1).14 
For cases in which the diagnosis remains ambiguous, immunophenotyping or molecular 
genetic analysis to assess B-cell clonality may be employed. The later is accomplished by 
polymerase chain reaction (PCR)-based amplification of rearranged VDJ sequences of the 
heavy-chain immunoglobulin (Ig) gene. In terms of immunophenotype, there is no specific 
marker for MALT lymphoma at present. Tumour cells typically express IgM, CD20, CD79a, 
CD21, CD35 and show light chain restriction. MALT lymphoma can be differentiated from 
other B-cell lymphomas in the stomach, namely mantle cell lymphoma, lymphocytic 
lymphoma and follicular lymphoma, by the absence of characteristic markers CD5, CD10, 
CD23 and cyclin D1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Morphological features of gastric MALT lymphoma. a  Centrocyte-like neoplastic B cells surround 
reactive B-cell follicles (arrowheads) and invade the gastric glandular epithelium (G), resulting in 
lymphoepithelial lesions (LELs; arrows).15 b  Follicular colonisation leads to replacement of the B-cell follicle 
by neoplastic B cells with moncytoid appearance due to abundant pale staining cytoplasm.14 A rim of normal 
mantle zone is retained.16 c  Small neoplastic B-cells with a narrow rim of clear cytoplasm forming LELs.16 d  
Lymphoma cells resembling small lymphocytes with condensed chromatin.16 e  Tumour cells with nuclei 
resembling those of centrocytes, but with more abundant cytoplasm.16   
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Although most gastric MALT lymphomas present as localised disease at diagnosis, 
the tumour may disseminate both locally, to form multifocal lesions, and systemically.17 A 
prospective study involving over 200 patients detected involvement of the regional lymph 
nodes in 32% of cases and secondary tumours in extranodal sites in 11% cases.18 
Dissemination to the regional lymph nodes and the spleen typically involves the marginal 
zone around B-cell follicles.19 The tendency of dissemination to other parts of the 
gastrointestinal tract or the splenic marginal zone is due to high expression of the mucosal 
homing receptor α4β7 integrin by the lymphoma B cells.20, 21  
 
Table 1.1  Histological scoring for diagnosis of MALT lymphoma. Adapted from14. 
 
 
1.1.2 The Helicobacter pylori connection 
The paradox of MALT lymphoma arising in an organ naturally devoid of organised 
lymphoid tissue, was first resolved by Wotherspoon et al.22 in 1991, in a study linking H. 
pylori infection with gastric MALT lymphoma. H. pylori is a gram-negative microaerophilic 
bacterium that colonises the human gastric epithelium of approximately half the world's 
population.23 Multiple lines of evidence implicate a direct role for H. pylori in the 
pathogenesis of MALT lymphoma. First, H. pylori is present in the gastric mucosa of most 
cases of gastric MALT lymphoma, with infection rates ranging from 60% to over 90% of 
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cases.22, 24-26 Second, gastric MALT lymphoma has the highest incidence in geographical 
regions with high prevalence of H. pylori infection.3 Third, experimental infection of mice 
with various Helicobacter strains induces gastric MALT lymphoma-like lesions.27 Finally, a 
large case-control study provided definitive evidence for an association between previous H. 
pylori infection and the development of gastric, but not non-gastric lymphoma.28 
Interestingly, the frequency of H. pylori positivity at diagnosis is lower in gastric lymphoma 
than in chronic gastritis or peptic ulcer indicating loss of the ecological niche of the 
bacterium upon disease progression.24  
 
The notion of H. pylori as a gastric carcinogen is reinforced by the clinical and 
histological remission of some cases (approximately 75%) of low grade MALT lymphomas 
after H. pylori eradication by antibiotic therapy. 14, 29-31 To date, gastric MALT lymphoma is 
the only malignancy for which antibiotics are used as the first-line treatment. Direct evidence 
implicating H. pylori as the driving force in MALT lymphomagenesis came from in vitro 
studies wherein, crude tumour cell suspensions proliferated upon addition of heat-killed, 
whole-cell preparations of H. pylori.32 Importantly, this response was demonstrated to be 
specific for only one bacterial strain per case of lymphoma.32 In contrast, control experiments 
using nodal lymphoma cells failed to respond to any strain of Helicobacter. 
 
While H. pylori is accepted as the dominant human gastric bacterial pathogen in 
MALT lymphoma, a small percentage of human infections have been linked to another 
Helicobacter species, referred to as H. heilmannii. While this organism is the primary strain 
seen in primates, pigs and carnivorous mammals, only a small percentage of infections in 
humans (0.5-6%) have been attributed to H. heilmanni and transmission from animals has 
been suggested.33-35 Despite this low prevalence, an association with gastric MALT 
lymphoma has been demonstrated and eradication of the organism leads to tumour regression 
identical to that of H. pylori.36 
 
Although the causal relationship between H. pylori infection and gastric MALT 
lymphoma is well established, the reason why only a minority of infected individuals (<1%) 
develop MALT lymphoma is less clear. At present, no host susceptibility factor or 
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environmental factor predisposing a patient to MALT lymphoma has been revealed to shed 
light on the enigma. A recent study investigated, for the first time, the potential role of the 
host’s genetic background as a risk factor for gastric MALT lymphoma.37 Germline 
variations of MALT1 (which encodes MALT lymphoma translocation protein 1) were 
examined in a large cohort of patients with gastric MALT lymphoma but failed to 
demonstrate a clear link to disease susceptibility.37  
 
In addition to potential host and environmental factors, there are specific bacterial 
virulence genes that may determine the disease outcome. A close link exists between gastric 
carcinoma and Helicobacter strains that harbour the cag-pathogenicity island (cag PAI) and 
its secreted effector molecule CagA, as well as several other virulence factors such as IceA 
and the vacuolising cytotoxin VacA. In contrast, characteristics of H. pylori strains 
associated with MALT lymphoma are less clear. Existing studies have focused mainly on the 
role of CagA and its prevalence in strains isolated from MALT lymphoma. Epidemiological 
data from one study indicated that cagA-positive H. pylori is present in the gastric mucosa of 
most, if not all, patients with MALT lymphoma.38 In contrast, another group reported no 
significant association of cagA-positive H. pylori strains with lymphoma development.39 
Subsequent studies have compared the cagA genotype between low and high grade MALT 
lymphoma and found that indeed the incidence of cagA-positive H. pylori infection in 
gDLBCL was significantly higher than in low grade MALT lymphoma or gastritis.40, 41  
Altogether, these observations allude to an important role for cagA-positive H. pylori in the 
development and/or progression of gastric MALT lymphoma.  
 
1.1.3   Treatment and follow-up 
1.1.3.1   Treatment of low grade gastric MALT lymphoma  
Triple therapy, consisting of a combination of antibiotics, (clarithomycin, 
amoxicillin, tetracycline and/or metronidazole) with a proton pump inhibitor has become the 
first-line option for patients with localised, H. pylori-positive MALT lymphoma. 
Helicobacter eradication therapies have revolutionised the natural course of MALT 
lymphoma. In the past, surgical excision either alone or followed by radiotherapy or 
postoperative chemotherapy, was considered the gold-standard treatment until the early 
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1990s. These approaches resulted in five-year survival rates as high as 90%.5 The multifocal 
nature of this disease often necessitated a total gastrectomy (rather than partial resection) 
which carries a risk of morbidity and the potential to severely impair the patient’s quality of 
life. Surgical intervention for gastric MALT lymphoma is now only reserved for patients 
with local complications, such as GI haemorrhage.  
 
Since the introduction of H. pylori eradication therapy in 1993,14 several independent 
studies have confirmed its efficacy in the treatment of localised low grade MALT 
lymphomas.30, 42, 43 Tumours confined to the mucosa and submucosa are treated most 
effectively; whereas, tumours with involvement of the stomach wall or perigastric lymph 
nodes or lymphoma cases positive for the t(11;18)(q21;q21) translocation are typically 
refractory to eradication therapy.44-46 There is no standard treatment for patients not 
responding to eradication therapy; those with a negative H. pylori status are usually referred 
for radiation, chemotherapy, or immunotherapy, or combinations of these. Relatively low 
doses of involved-field radiotherapy (30-40 Gy over 4 weeks) can be applied to the stomach 
with good results.47 Immunotherapy with anti-CD20 monoclonal antibodies and/or 
chemotherapy is usually set aside only for patients with disseminated disease.48  
 
Several studies have provided molecular evidence that monoclonal tumour cells can 
persist long after complete histological remission following successful H. pylori 
eradication.29, 30, 49 Such patients are considered to have ‘minimal residual disease’ and are at 
a significantly higher risk of relapse.50 However, a conservative ‘watch and wait’ strategy 
with regular endoscopies and biopsies is the recommended approach for patients with 
minimal residual disease.51 In general, relapse rates in patients treated for the infection alone 
vary between 1-20%.42, 52-54 Serial gastric biopsies are therefore mandatory for the 
surveillance of patients following eradication therapy alone. Endoscopic examination is 
recommended 2-3 months after termination of antibiotic treatment to confirm H. pylori 
eradication, followed by endoscopy every 6 months for 2 years.55  
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1.1.3.2 Treatment of gastric diffuse large B-cell lymphoma 
Nearly 60% of gastric lymphomas are high grade lesions with or without a low 
grade MALT component.56 These lymphomas are generally H. pylori independent and are 
therefore resistant to antibiotic therapy. However, like MALT lymphoma, treatment of 
gDLBCL has undergone a dramatic shift away from surgical management with the current 
treatment options favouring chemotherapy and radiation therapy according to the extent of 
disease. The most common regimen for localised disease is immuno-chemotherapy entailing 
a short course of R-CHOP (Rituximab plus cyclophosphamide, doxorubicin, vincristine and 
prednisone) for three or four cycles followed by involved-field radiotherapy. Evidence has 
recently surfaced that some cases of high grade gastric MALT lymphoma might still be 
responsive to H. pylori antigenic drive and may be cured with eradication therapy.29, 57 
However, prospective studies with large patient numbers are warranted to validate these 
results and may help to identify factors that predict a favourable response to H. pylori 
eradication in order to avoid more aggressive treatment strategies. 
 
1.1.4 Pathogenesis of gastric MALT lymphoma  
The evolution of gastric MALT lymphoma is a multistep process that results in 
transformation from a reactive polyclonal B-cell population to a neoplastic monoclonal 
lymphoproliferation (Figure 1.2). H. pylori infection induces chronic activation of the 
immune system and triggers sustained lymphoid proliferation. Gastric MALT lymphoma 
therefore constitutes a unique type of infection-associated lymphoma, in which the infectious 
agent does not directly infect and transform lymphoid cells. In this context rather, the 
microbial pathogen is considered a chronic source of antigen. The molecular mechanisms 
underlying this indirect lymphomagenesis await precise elucidation. Mounting evidence 
implicates factors such as, signalling via surface Ig, T-cell derived costimulatory signals and 
the acquisition of genetic abnormalities as important driving forces in the early stages of 
MALT lymphoma pathogenesis.  
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Figure 1.2  Hypothetical model depicting the multistage development of gastric MALT lymphoma. 
Persistent H. pylori infection attracts B cells, T cells and neutrophils to the gastric mucosa. B-cell proliferation 
is driven by CD40–CD40 ligand interaction with H. pylori-activated, reactive T cells, as well as by cytokines. 
The chronic proliferative state of these B cells, as well as neutrophil-mediated release of reactive oxygen 
species in areas of chronic inflammation, induces additional oncogenic events that eventually make 
lymphoproliferation independent of antigenic stimulation. H. pylori eradication therapy inhibits (red arrows) 
these tumour-promoting processes, although t(11;18)(q21;q21)-positive MALT lymphomas are less likely to 
respond to this therapy than are tumours without this translocation. Additional genetic alterations in 
t(11;18)(q21;q21)-negative MALT lymphomas can ultimately result in transformation to clinically aggressive 
diffuse large B-cell lymphoma. Reproduced from Sagaert et al., 2010.15   
 
1.1.4.1 Gastric MALT acquisition  
The acquisition of organised lymphoid tissue is the first step towards lymphoma 
development in the stomach. Under normal physiological conditions, the gastric mucosa is 
devoid of organised lymphoid tissue. H. pylori, unlike other microorganisms, has evolved the 
unique ability to survive in the stomach by secreting the enzyme urease that converts urea to 
ammonia leading to reduced acidity of the stomach. With age, the combination of infection 
and decreased acidity of the stomach elicits the accumulation of lymphocytes and thus the 
formation of MALT.   
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1.1.4.2 Role of Infiltrating T cells  
Current evidence indicates that MALT lymphoma cells do not grow autonomously, 
rather they are dependent on T-helper cell-derived activation and proliferation signals. MALT 
lymphomas are invariably infiltrated by high numbers of activated, immunocompetent 
memory T cells, with an estimated ratio of CD4+/CD8+ cells of approximately 4:1 (Figure 
1.3).10, 11 Koulis et al.58 demonstrated that the proliferating fraction of tumour-infiltrating 
cells were exclusively CD4+ helper T cells. Antigen-specific activation of infiltrating T cells 
was demonstrated by their expression of CD40-ligand,10, 58 a co-stimulatory molecule 
necessary for effective B-cell/T-cell interaction. Tumour-infiltrating T cells highly express 
the immunocompetence marker CD28, which binds to the B7-related surface proteins CD80 
and CD86 on antigen-presenting cells and permits optimal activation of T cells upon antigen 
recognition.11, 58 Expression of the costimulatory molecules CD80 and CD86 has been 
demonstrated in MALT lymphomas cells.58-60 
 
 
 
Figure 1.3  Tumour-infiltrating T cells are predominantly CD4+ and of the type 2 helper T-cell (Th2) 
Type. Serial cryosections of a representative murine lymphoid aggregate were stained blue-grey with 
monoclonal antibodies against the indicated antigens and counterstained with nuclear fast red. B220+ B cells 
constitute the predominant cell type. CD3+ T cells are abundant, whereas F4/80+ macrophages are present at 
very low numbers and found only around the edges of the tumour. Lymphoid aggregates are colonised by CD3+ 
T cells, but not F4/80+ macrophages. Tumour-infiltrating T cells are mostly CD4+ and produce IL4, but not 
IFN-γ. Reproduced from Mueller et al., 2005.11  
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Several lines of evidence suggest that H. pylori-specific activated tumour-infiltrating 
T cells provide growth signals to the tumour B cells. Hussell et al.32, 61 first demonstrated that 
cultures of explanted, unsorted tumour cells proliferate in response to H. pylori extract. 
Removal of tumour-associated T cells from the culture system abrogated proliferation, 
suggesting that their growth is driven by the presence of T cells.61 This reaction has been 
shown to be strain specific and site dependent indicating that T cells are responding to H. 
pylori-derived antigens.62 In contrast, high grade MALT lymphomas do not respond to H. 
pylori stimulation in vitro.62 These observations partly explain the proclivity of low grade 
tumours to remain localised to the primary site and regress after H. pylori is eradicated with 
antibiotics.  
 
Greiner et al.63 showed that the tumour cells are responsive to CD40 stimulation (via 
ligation of the CD40 receptor by an agonistic antibody) in the presence of Th2 derived 
cytokines IL4 and IL10, but not Th1 cytokines IFN-γ or IL2 (Figure 1.4). Combinations of 
both IL4 and IL10 in this CD40 culture system synergised to induce marked proliferation of 
low grade MALT lymphoma cells.63 In contrast, high grade MALT lymphomas responded 
significantly to CD40 signal alone and in combination with either Th1 or Th2 derived 
cytokines.63 In line with this evidence, infiltrating T cells of low grade MALT lymphoma 
typically express high levels of CD40L and Th2 cytokines (Figure 1.3), with the neoplastic B 
cells being positive for CD40.10, 11, 58 Most high grade tumours have been shown to lack 
CD40L expression which again implies a different role for infiltrating T cells in the high 
grade scenario.59 Further supporting the critical role of a Th2 helper response in MALT 
lymphomagenesis, is the fact that these lymphomas only develop in mouse strains with a 
genetic predisposition towards Th2 polarisation, such as BALB/c. 
 
D’Elios et al.64 observed that T cells derived from MALT lymphoma exhibited both 
defective perforin-mediated cytotoxicity and poor ability to induce apoptosis. Deficient 
cytotoxic control of B-cell growth thus provides a plausible explanation for their enhanced 
helper activity on B-cell proliferation. Current evidence therefore sustains the notion that 
tumour-infiltrating T cells do not represent a host immune response, but rather are part of a 
T-cell dependence underlying the antigen-driven development of gastric MALT lymphomas. 
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Additional studies are clearly necessary to further characterise this infiltrating T-cell 
population and elucidate the relative contribution of T-helper derived signals to MALT 
lymphoma growth in vitro and in vivo. 
 
Figure 1.4  Induction of low grade (a) and high grade (b) MALT lymphoma B-cell proliferation by anti-
CD40 and cytokines. 5 x 104 tumour B cells from 6 low grade and 5 high grade MALT lymphoma patients 
were cultured in triplicate with or without cytokines and anti-CD40 as indicated. B-cell proliferation was 
determined at day 5 of culture by the addition of [3H] thymidine during the last 16 hours of the culture period. 
The proliferation index is expressed as cpm assay/cpm medium. The results give the cumulative mean value 
from three independent proliferation tests performed for each patient. Each error bar gives the standard 
deviation of the respective cumulative mean. Reproduced from Greiner et al., 1997.63 
 
 
1.1.4.3 MALT lymphoma as an antigen-driven neoplasm 
Direct and indirect evidence alludes to a pathogenic role for antigen in MALT 
lymphomagenesis, whereby tumour cells may receive signals via antigenic stimulation 
through their B-cell receptor (BCR). Direct evidence comes from the observation that a 
proportion of low grade gastric MALT lymphomas respond favourably to bacterial 
eradication alone.14, 65 The concept of an antigen-driven lymphomagenesis is indirectly 
supported by analysis of the variable part of the Ig heavy chain (VH) gene from tumour cells. 
MALT lymphoma B cells carry rearranged and somatically mutated Ig genes, confirming 
their origin from antigen activated memory B cells.66, 69 Multiple studies examining antigenic 
selection of the VH genes have reported evidence of positive selective pressure, suggesting 
that MALT lymphoma B cells have undergone the germinal centre reaction and affinity 
maturation.63, 67, 68 Preferential use of VH family genes (VH4, VH3 and VH1) previously 
associated with autoreactivity and polyreactivity has also been noted.66, 69 In addition, 
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ongoing mutation, as indicated by intraclonal variation of the Ig sequence, exists in low grade 
tumours which suggests continued antigenic stimulation is important in clonal B-cell 
expansion.68, 70, 71   
 
The occurrence of somatic hypermutation and intraclonal variation in MALT 
lymphoma strongly bolsters a role for antigen, given these processes are antigen-driven. Of 
note, the ongoing mutation rate dissipates as low grade tumours progress, and eventually 
disappears in some gDLBCLs.68, 72 The lack of ongoing mutation in high grade tumour cells 
may reflect the loss of ability to respond to direct antigen stimulation. This is currently 
thought to be the result of an accumulation of genetic defects, rendering the lymphoma less 
dependent on antigenic stimulation over time. A confounding feature of MALT lymphoma is 
that the Ig gene locus undergoes somatic hypermutation yet avoids class switch 
recombination (CSR), indicating that IgM+ tumour cells are favoured by selective forces. 
Retention of IgM expression in MALT lymphoma is thought to be due to their propensity to 
undergo an aberrant form of switch recombination, i.e. only one rather than two switch 
regions are involved, leading to an abnormal rearrangement of the IgH switch region and 
conservation of IgM status.73  
 
Despite strong support for antigen as a pathogenic factor in MALT lymphomagenesis, 
the search for a target ligand has proven to be difficult and has yielded controversial results. 
This may be attributable to the different approaches used to generate tumour-derived 
antibody and the subsequent screening methods applied. The tumour Ig specificity may also 
depend on the anatomical location from which the lymphoma originates. Hussel et al.172 first 
addressed the issue of Ig specificity using anti-idiotypic antibodies derived from three cases 
of gastric MALT lymphoma; the authors detected polyreactivity in one case and described 
reactivity towards follicular dendritic cells and mucosal post capillary venules in the others. 
Greiner et al.75 also did not identify a specific antigen, but concluded that the target ligand is 
a common antigen of IgA+ and IgM+ mucosal B cells. Lenze et al.76 screened seven single-
chain fragment variable antibodies derived from gastric and non-gastric MALT lymphomas 
but failed to identify binding partners for the majority of the Igs analysed. Finally, Bende et 
al.66 reported that many MALT lymphomas express B-cell receptors with strong homology to 
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rheumatoid factors (RFs), i.e. antibodies with auto-IgG binding capacity. Specifically, the 
authors found that 8 of 45 gastric (18%), 13 of 32 salivary gland (41%) and none of the 19 
(0%) pulmonary MALT lymphomas expressed antigen receptors with strong RF homology; 
experimentally they confirmed this finding for 7 of 10 antibodies analysed.66 However, the 
bulk of these antibodies were derived from parotid gland lymphomas, with only 2 being 
derived from gastric tumour Igs.66 A more comprehensive study is therefore desired to assess 
the antigen specificity of gastric MALT lymphoma Ig and to further determine whether 
signalling through the B-cell receptor directly contributes to the proliferation of these 
malignant lymphocytes.  
 
1.1.4.4 Genetic abnormalities  
H. pylori infection triggers not only an immunological response that stimulates the 
growth of neoplastic B cells, but also elicits an inflammatory response by attracting and 
activating neutrophils. The subsequent release of reactive oxygen species (ROS) by 
neutrophils are suspected to cause a wide range of genetic damage, principally double-strand 
DNA breaks.77 Moreover, the inherent genetic instability of B cells during somatic 
hypermutation and class‑switch recombination further exacerbates the risk of oncogenic 
DNA damage78 during the prolonged proliferation of B cells induced by chronic 
inflammation. 
 
A characteristic spectrum of genetic defects in MALT lymphomas have been 
detected in recent years. Abnormalities include trisomy of chromosomes 3, 7, 12 and 18 as 
well as the chromosomal translocations t(1;14)(p22;q32), t(14;18) (q32;q21), 
t(11;18)(q21;q21) and t(3;14)(p13;q32) which result in IGH-BCL10, IGH-MALT1, BIRC3-
MALT1 and IGH-FOXP1 rearrangements, respectively. These genetic aberrations occur at 
variable frequencies according to the anatomic location of the tumour (Table 1.2). It is 
noteworthy that the shared outcome of the majority of these genetic aberrations is the 
constitutive activation of the nuclear factor-κB (NF-κB) signalling pathway (Figure 1.5).  
NF-κB is a key transcription factor in immunity, as it regulates the expression of a number of 
genes involved in B-cell proliferation and survival.79, 80 Constitutive activation of NF-κB by 
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genetic abnormalities results in uncontrolled B-cell proliferation and thus contributes to the 
neoplastic transformation of the B-cell clone.  
 
Table 1.2  Frequency of chromosomal translocations in MALT lymphoma. Adapted from8, 15.   
 
  
 
Translocations 
The translocation t(11;18)(q21;q21) represents the most frequent structural 
chromosomal abnormality in gastric MALT lymphoma, accounting for up to 26% of cases.81 
In contrast to t(11;18)-positive tumours, t(14;18), t(1;14) and t(3;14) translocations mainly 
arise in non-gastric tissues and are therefore not discussed further. Remarkably, in most 
t(11;18)-positive cases it appears to be the sole chromosome aberration.82, 83 In contrast, cases 
lacking this translocation exhibit a wide range of chromosomal aberrations.83, 84 Lymphomas 
with this translocation are invariably refractory to H. pylori eradication therapy and are more 
likely to show dissemination to regional lymph nodes or distal sites.85, 86 Initially, it was 
believed that t(11;18)-positive tumours rarely, if ever, evolved into gDLBCL.85 However, 
recent work has shown that gDLBCLs exhibit this translocation at equivalent frequencies to 
low grade gastric MALT lymphomas and therefore its presence does not exclude high grade 
transformation.87 The translocation t(11;18)(q21;q21), fuses the amino-terminus of the 
BIRC3 (baculovirus inhibitor of apoptosis protein repeat-containing protein 3) gene (on 
chromosome 11q21) to the carboxyl-terminus of the MALT1 gene (on chromosome 18q21) to 
create the chimeric BIRC3-MALT1 protein. BIRC3 suppresses apoptosis by inhibiting the 
activity of caspases 3, 7 and 9, whereas MALT1 is involved in antigen-receptor-mediated 
NF-κB activation. How the BIRC3-MALT1 fusion precisely contributes to MALT 
lymphoma development remains to be eludicated.  
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Trisomy 3 
Cytogenetic and fluorescence in situ hybridisation (FISH) studies have revealed a 
high frequency of trisomy 3 in gastric MALT lymphoma.88, 89 However, it is also the most 
common form of aneuploidy described in other types of non-Hodgkin’s lymphoma. The 
genetic mechanism by which trisomy 3 may contribute to lymphomagenesis has not yet been 
experimentally addressed. However, an increased gene dosage effect resulting from higher 
copy numbers of genes relevant to lymphoma development is likely to explain the biological 
consequences underlying chromosomal trisomies.90 Several promising candidate genes are 
located on chromosome 3 which have been implicated in lymphomagensis, such as the proto-
oncogene BCL6 and the transcription factor FOXP1 (described in more detail in section 
1.1.5).  
 
Epigenetics 
In recent years, evidence for the involvement of epigenetic mechanisms in the 
initiation and development of MALT lymphoma has began to emerge. Attention has focused 
solely on the epigenetic phenomenon of DNA hypermethylation which entails the enzymatic 
addition of a methyl group to the carbon 5 position of a cytosine that precedes a guanosine in 
the DNA sequence (termed CpG dinucleotide). This covalent modification of DNA is 
catalysed by DNA methyltransferases (DNMTs) and is associated with transcriptional 
silencing.91 Min et al.92 demonstrated CpG hypermethylation of the tumour suppressor genes 
TP16 and TP57 in 41.7% and 29.2% of low grade MALT lymphoma cases, respectively. A 
different group analysed the methylation status of eight CpG islands, including those of 
TP15, TP16, TP73, hMLH1, DAPK, MINT1, MINT2 and MINT31 in H. pylori dependent and 
independent MALT lymphomas93 The authors found that H. pylori dependent MALT 
lymphomas exhibited at least four methylated genes, while H. pylori independent cases 
displayed lower methylation levels with less than two methylated genes.93 This suggests that 
chronic inflammatory conditions induced by H. pylori infection may promote DNA 
methylation in reactive lymphocytes. Other epigenetic mechanisms such as covalent 
modification of histones or microRNA mediated gene regulation have not yet been studied in 
the context of MALT lymphoma.   
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Figure 1.5  The different chromosomal translocations involved in MALT lymphoma affect a common 
molecular pathway. Following antigen-receptor stimulation, CARD11 is activated to recruit BCL10 through 
caspase recruitment domain (CARD)–CARD interactions, and this induces BCL10 oligomerisation. BCL10 
then binds the immunoglobulin (Ig)-like domain of MALT1 through a short region downstream of its CARD 
and induces MALT1 oligomerisation. Oligomerised MALT1 binds to and activates tumour-necrosis factor 
receptor associated factor 6 (TRAF6). Activated TRAF6 interacts with a ubiquitin-conjugating enzyme (E2) and 
mediates polyubiquitylation of nuclear factor-κB (NF-κB) essential modulator (NEMO). Multi-ubiquitylated 
NEMO induces the activation of IKKα and IKKβ, which causes phosphorylation and degradation of IκB and 
the release of NF-κB. NF-κB then translocates to the nucleus and transactivates genes important for 
lymphomagenesis. In MALT lymphomas involving t(1;14)(p22;q32), BCL10 is overexpressed and thought to 
form oligomers through its CARD domain without the need of upstream signals, leading to constitutive NF-κB 
activation. In MALT lymphomas with t(14;18)(q32;q21), MALT1 is overexpressed and the oligomerisation and 
activation of MALT1 is thought to be dependent on BCL10. In MALT lymphomas with t(11;18)(q21;q21), the 
resulting API2–MALT1 fusion product is believed to self-oligomerise through the baculovirus IAP repeat (BIR) 
domain of the API2 molecule, therefore leading to constitutive NF-κB activity. Casp-L, caspase-like domain; 
CC, coiled coil; DD, death domain; GUK, guanylate-kinase-like domain; SH3, Src homology 3 domain; Ub, 
ubiquitin; Z, zinc finger. Reproduced from Isaacson and Du., 2004.94 
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1.1.5 Molecular basis of high grade transformation  
The molecular events underlying the transition of an indolent low grade MALT 
lymphoma to a clinically aggressive DLBCL are ill-defined, but are of considerable interest 
due to the poor prognosis and limited treatment options associated with the latter disease. 
Although an accumulation of genetic aberrations clearly contributes to high grade 
transformation, many of the genetic abnormalities that appear to characterise the nodal form 
of DLBCL, such as BCL2 rearrangements, are absent in gDLBCL. Genetic alterations that 
have long been associated with histological transformation of MALT lymphoma include, 
complete inactivation of the TP53 gene, hypermethylation of the promoter region of TP15 
and TP16 as well as deletion of the TP16 gene.95-97 It has further been shown that in contrast 
to low grade MALT lymphoma, some gDLBCLs overexpress the BCL6 protein or harbour 
rearrangements of the BCL6 locus on chromosome 3p27.98-100 BCL6 acts as a transcriptional 
repressor and is required for GC formation and affinity maturation as well as being involved 
in cell-cycle arrest, inflammtion and apoptosis.101-103 
 
In light of these early findings, Starostik et al.84 recently compared the allelotypes of 
MALT lymphoma with gDLBCL via microsatellite screening and found amplification of the 
region 3p26.2-3p27 to be the most frequent aberration in both disease entities (Figure 1.6). 
The authors proposed that this aberration (harbouring the BCL6 locus) may be a significant 
marker for high grade transformation of a proportion of MALT lymphomas.84 The study 
further revealed that allelic imbalances in the 11q23-24 and 18q21 regions occurred with 
comparable frequencies in both low and high grade tumours.84 Aberrations in regions 6q23.3-
25 and 7q31 were present at a higher rate in gDLBCLs.84 While, allelic imbalances in regions 
2p16-21, 6p23 (A20), 12p12-13, 5q21, 9p21 (TP16), 13q14 (RB) and 17p13 (TP53) occurred 
exclusively in gDLCBL.84 Although some of these deletion hotspots comprise known tumour 
suppressor genes (indicated in parentheses), the proportion of the allelic imbalances that are 
of biologic or clinical relevance to gDLBCL remains largely unclear.   
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Figure 1.6  Comparison of the allelotypes 
of low grade MALT lymphoma and 
DLBCL. Frequency of allelic imbalance in 
individual regions is expressed as a bar 
diagram: open bar, amplification; black 
bar, deletion. The left-hand side shows 
results for MALT lymphoma (MZBCL); 
the right-hand side, results for DLBCL. 
Reproduced from Starostik et al., 2002.84 
 
 
 
 
 
 
 
 
 
Disease progression and high grade transformation has also been linked to 
rearrangements of the MYC proto-oncogene. The MYC gene, located at chromosome band 
8q24, encodes a basic helix-loop-helix transcription factor that modulates the expression of 
an expansive network of genes involved in cell proliferation, growth and apoptosis.104 In 
stark contrast to their nodal counterparts, previous studies have reported that MYC 
rearrangements are reasonably frequent in gDLBCLs and therefore the deregulation of MYC 
expression might be an important factor in extranodal DLBCL. Van Krieken et al.105 first 
noted in 1990, the presence of MYC rearrangements in 50% of high grade lymphomas of the 
stomach and the utter lack thereof in low grade lymphomas. This trend was swiftly 
reinforced by an independent study which found structural alterations of the MYC gene in 
60% of DLBCLs derived from the stomach.106 Likewise, Kramer et al.107 reported that 60% 
of gDLBCLs versus 2% of nodal cases analysed were affected by MYC gene 
rearrangements. In contrast, a study by Peng et al. did not identify MYC rearrangements in 
any of the eleven cases of high grade MALT lymphoma examined, thereby arguing against 
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the potential involvement of MYC gene rearrangements in high grade lymphomagensis.108 
This group also compared the mutation frequency within the MYC gene between low and 
high grade MALT lymphoma but found no significant differences between the disease 
entities, indicating the mutations may have been acquired during early development of the 
tumours.108   
 
The putative oncogene FOXP1, located at 3p13, codes for a member of the FOX 
family of transcription factors which are characterised by a common DNA-binding winged 
helix or forkhead domain. FOXP1 is known to play an important role in B-cell development, 
since FOXP1-null mice exhibit impaired early B-cell development with a block at the 
transition from pro-B to pre-B cells.109 FOXP1 was recently identified as a novel 
translocation partner of IGH, not only in MALT lymphoma but also in extranodal DLBCL.110 
The overall incidence of FOXP1 gene rearrangements is, however, rare and a substantial 
number of t(3;14)(p13;q32)-negative cases have strong nuclear FOXP1 expression.110, 111 
This discrepancy suggests alternative mechanisms, other than underlying genetic alterations, 
as the responsible cause for FOXP1 deregulation. Interestingly, correlation studies have 
implicated FOXP1 deregulation in high grade transformation of MALT lymphoma to 
gDLBCL.111, 112 In one study, Saegert et al.112 reported the significant association of FOXP1-
positivity with a five-year disease-free survival rate of 50% in patients compared to 100% in 
the FOXP1-negative group. In addition, the authors observed that all of the MALT 
lymphomas in the study which transformed into gDLBCL exhibited strong FOXP1 
expression.112 Despite the clinical implications of aberrant FOXP1 expression, no attempts 
have yet been made to precisely define the oncogenic mechanism(s) of this transcription 
factor. 
 
A novel mechanism inducing genetic instability, termed aberrant somatic 
hypermutation (ASHM), has been described in the context of both nodal and gastric forms of 
DLBCL.113, 114 Furthermore, this phenomenon appears to be associated with high grade 
transformation of chronic lymphocytic leukaemia (CLL).115 Somatic hypermutation normally 
targets the 5′ end of IGV genes in GC B cells, but in some lymphomas it appears to misfire 
and aberrantly target multiple loci, including proto-oncogenes: PIM1, PAX5, RHOH and 
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MYC.113 Sequence analysis of MALT lymphomas revealed that 75% of low grade MALT 
lymphomas and 100% of gDLBCLs contained mutations in one or more of these 
oncogenes.107 Since higher frequencies of mutations were found in transformed MALT 
lymphoma, an active involvement of ASHM in high grade transformation has been 
speculated. By mutating important oncogenes, ASHM may therefore represent a major 
contributor to the pathogenesis and ultimate transformation of MALT lymphoma.   
 
1.1.6 Animal models of Helicobacter-induced MALT lymphoma  
 The recognition of H. pylori as the etiological agent behind the formation of MALT 
lymphoma necessitated the development of an animal model to help elucidate the pathogenic 
mechanisms of this bacterium and facilitate the development of improved treatment 
strategies for the disease. An appropriate model was first achieved in 1995 in the laboratory 
of Adrian Lee following a series of experiments examining the effects of long-term 
colonisation by Helicobacter stains in BALB/c mice.27 Infection of mice with a Helicobacter 
strain isolated from cats, H. felis, was found to induce acquisition of MALT and lead to the 
formation of gastric lymphomas after approximately 18-24 months (Figure 1.7).27 The 
murine form of MALT lymphoma accurately mimics the histopathological features observed 
in human patients.  
 
 H. felis readily colonises murine stomachs at high densities and by 22 months post-
infection up to 90% of animals develop LELs, a hallmark of MALT lymphoma in humans 
(Figure 1.7).27 This model has been further validated by the demonstration of lymphoma 
regression following antibiotic eradication of H. felis from tumour-bearing mice.116 Animals 
received a triple therapy consisting of bismuth subcitrate, metronidazole and tetracycline at 
20 months post-infection; by four months post-treatment no lymphoid follicles were detected 
in the antibiotic-treated animals and only 10% of the animals had LELs.116 Several studies 
have since highlighted that 10-25% of animals fail to respond to antimicrobial therapy, a 
result consistent with the remission rate in human patients.11, 116 Interestingly, transcriptional 
profiling of whole stomach tissue from successfully treated mice revealed the long-term 
mucosal persistence of residual B cells.11 This discrepancy between histologic and molecular 
remission is similar to the phenomenon observed in human patients, where the persistence of 
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monoclonal B-cells in the gastric mucosa occurs in roughly 50% of patients with complete 
histological remission.49, 117 Mueller et al.11 further reported that experimental reintroduction 
of Helicobacter in treated mice led to very rapid disease recurrence, with relapsed tumours 
exhibiting more aggressive behavior. Additional studies using this murine model have 
uncovered distinct transcriptional profiles that correlate with specific histopathological 
disease stages and allow accurate prediction of treatment outcome.119 
 
 
Figure 1.7  Histologic features of MALT lymphoma-like lesions in mice infected with H. felis. a  Nodular 
gastric mucosa (arrows) of H. felis-infected BALB/c mouse; A = antrum; C = corpus mucosa. b  Section 
through nodular mucosa showing lymphoid hyperplasia in the submucosa. Poorly demarcated germinal centres 
(arrows) are apparent within the lymphoid tissue (H&E). c  Small aggregates of centrocyte-like cells (arrows) 
infiltrate hyperplastic foveolar epithelium in a relatively early lymphoepithelial lesion (LEL)(H&E). d  Fully 
developed LEL lesion showing destruction of glandular and foveolar epithelium with a central epithelial 
remnant (arrows)(H&E). Reproduced from Enno et al., 1995.27   
 
A comprehensive study comparing the virulence of H. pylori, H. felis and H. 
heilmannii in groups of BALB/c mice revealed the formation of lymphomas by all three 
species.119 Although the appearance of the lesions were indistinguishable, H. heilmannii 
induced the most severe response in the highest proportion of infected animals.119 However, 
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due to the difficulties involved in preparing H. heilmanni isolates, H. felis remains the 
preferred strain for experimental infection. Alternative animal models have also been 
sporadically employed to study MALT lymphoma. For instance, gastric MALT lymphomas, 
similar in morphology to those seen in humans, have been observed in ferrets infected with 
H. mustelae.120 
 
1.2 MicroRNA and cancer  
 
miRNAs represent an abundant class of small non-coding RNAs of ~18-25 
nucleotides in length that negatively regulate eukaryotic gene expression at the post-
transcriptional level. First identified in 1993 as regulators of developmental timing in 
Caenorhabditis elegans,121 miRNAs are now recognized as central players in a plethora of 
important human biological processes such as development, differentiation, haematopoiesis, 
metabolism, cell cycle and apoptosis. Rapidly accumulating evidence implicates a direct role 
for miRNAs in cancer etiology and such studies have begun to significantly improve our 
understanding of carcinogenesis with important ramifications for disease diagnosis and 
treatment. Exploring the role of miRNAs in MALT lymphoma represents an exciting and 
thus far unprecedented avenue of research that could provide meaningful insight into the 
development and progression of this disease. Since direct studies on the role of miRNAs in 
MALT lymphoma are lacking, the following chapter will focus on the general connection 
between miRNA biology and tumourigenesis. 
 
1.2.1 Biogenesis and mode of action  
Human miRNA genes are non-randomly distributed in the genome as either single 
genes or, for a considerable part, in clusters of 2-7 genes. It is postulated that a given cluster 
is under the control of a single promoter and is transcribed as a polycistronic primary 
transcript from which the individual miRNAs are processed. While the majority of miRNA 
genes are situated in intergenic regions, a substantial proportion (~40%) are also located 
within introns or exons of both protein-coding and non-coding genes and may therefore be 
co-transcribed with their host-gene. In mammals, miRNAs are initially transcribed by RNA 
polymerase II as long primary transcripts characterised by hairpin structures (pri-miRNAs) 
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and subsequently processed in the nucleus by the RNAse III Drosha into miRNA precursors 
(pre-miRNAs) of ~70 nucleotides in length (Figure 1.8). These precursor molecules are 
transported to the cytoplasm by an Exportin-5 mediated mechanism. In the cytoplasm, 
another RNAse III enzyme, termed Dicer, converts pre-miRNAs to imperfect dsRNA 
duplexes of approximately 22 nucleotides (miRNA:miRNA*) that contain both the mature 
miRNA (miRNA*) and its complementary strand. The duplex is unwound by a RNA helicase 
and the mature miRNA strand is incorporated into the complex known as miRNA-containing 
RNA-induced silencing complex (RISC), whereas the remaining strand is most probably 
degraded.122 As part of the RISC complex, mature miRNA is able to suppress target mRNA 
expression, mostly through interaction with the 3' untranslated region (UTR) leading to 
degradation or translation inhibition of the mRNA template (Figure 1.8) Although the degree 
of complementarity shared between miRNAs and their targets is an important factor, the 
exact molecular mechanisms that underlie post-transcriptional repression by miRNAs 
(reviewed in123) remain controversial. 
 
 
 
 
Fig 1.8  Biogenesis, maturation, and 
function of microRNAs (miRs). miRs are 
first transcribed by RNA polymerase II (Pol 
II) as long primary transcripts characterised by 
hairpin structures (pri-miRs) and processed in 
the nucleus into ~70-nucleotide-long pre-miRs 
by the microprocessor complex formed by 
RNAse III Drosha and its binding partner, 
DiGeorge critical region 8 (DGCR8). This 
precursor molecule is transported to the 
cytoplasm by Exportin 5. Pre-miRs are 
processed into miR:miR* duplexes of 
approximately 22 nucleotides by RNAse III 
Dicer. One strand of the miR:miR* duplex is 
then incorporated into the RNA-induced 
silencing complex (RISC), whereas the other 
strand is likely subjected to degradation. As 
part of this complex, the mature miR acts on 
its target by binding to the 3' untranslated 
region of target mRNAs leading to 
translational inhibition or mRNA cleavage, 
depending, at least in part, on the level of 
complementarity between the small RNA and 
its target sequence. Reproduced from Iorio 
and Croce et al., 2009.124 
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1.2.2     MicroRNA deregulation in cancer 
 
1.2.2.1  Evidence for the role of microRNA in cancer 
Cancer is a disease characterised by multi-step changes in the genome. To date, 
cancer research has largely focused on altered expression of protein coding genes. However, 
mounting evidence suggests that alterations of miRNAs also contribute to tumourigenesis. 
Direct evidence for the involvement of miRNAs in cancer was first reported by Calin et al.125 
who found two miRNAs, miR-15a and miR-16-1, clustered at chromosome 13q14, a region 
deleted in more than 50% of CLL cases. These miRNAs were found to target BCL2, an 
oncogene commonly overexpressed in CLL patients, thus establishing a tumour suppressive 
function for the miR-15a/miR-16-1 cluster.126 Several groups have since described aberrant 
miRNA expression patterns in a wide array of cancers including various haematological 
malignancies127-129 and solid tumours.130-133 The advent of high-throughput miRNA 
quantification technologies, such as microarray134, 135 and real-time PCR-based assays136, 137 
have permitted the identification of global miRNA profiles of whole cancer genomes 
including distinct miRNA expression signatures associated with the diagnosis, prognosis and 
response to therapy of several tumour types.127, 130, 131, 138-140 Surprisingly, it has become 
evident that despite the much smaller number of miRNA genes (~700) compared to protein 
coding genes (~22,000), the miRNome is a superior means for classifying cancer type and 
tumour stage, compared to the mRNA expression profile.130-132 In cancer, miRNAs have the 
propensity to function as either oncogenes or tumour suppressors, depending on their target 
mRNA. Although some miRNAs are overexpressed, the majority are downregulated in 
cancer with respect to normal tissue.130, 140, 141 This phenomenon has led to the hypothesis 
that global miRNA expression reflects the state of cellular differentiation130 and therefore the 
widespread repression of miRNA may represent a hallmark of human cancer.  
 
1.2.2.2  Mechanisms of microRNA deregulation  
 In normal development, miRNA expression is tightly regulated, both spatially and 
temporally in a highly tissue-specific manner.142 Aberrant expression of miRNAs, indicative 
of a disease state, can be caused by various mechanisms including deletions, amplifications 
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or mutations involving miRNA loci, epigenetic factors, transcriptional deregulation and 
defects in miRNA processing (Figure 1.9).  
 
 
 
Fig 1.9. Various mechanisms of microRNA (miR) regulation. Deregulated miR expression observed in 
cancer can be caused by chromosomal abnormalities, mutations, polymorphisms (SNPs), transcriptional 
deregulation, defective processing and epigenetic changes. Reproduced from Iorio and Croce et al., 2009124  
 
 
Genomic abnormalities  
Cancer is often accompanied by chromosomal abnormalities and a significant 
proportion of human miRNAs appear to reside in regions frequently rearranged in human 
cancer (Table 1.3)143-146 and in mice miRNA genes are often located at cancer susceptibility 
loci.147 Emerging evidence suggests that germ-line and/or somatic mutations and 
polymorphisms of miRNAs might also contribute to deregulation of mature miRNAs.148 For 
example, a G to A germ line mutation 19 nucleotides downstream of the pre-let-7e miRNA 
detected in human tumours, led to a significant reduction of its expression.149 Likewise, a 
germ line mutation (C to T) situated seven nucleotides downstream of the pre-miR-16-1 
sequence was identified in CLL patients and found to significantly reduce the expression of 
both miR-15a and miR-16-1.148 Mutations can also affect the target mRNA site; this concept 
was highlighted by a discovery in papillary thyroid carcinoma, where 50% of patients 
harboured point mutations within the KIT oncogene precisely mapping to the 3'UTR binding 
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domain for miR-221 and miR-222.150 Felli et al.151 previously described the ability of miR-
221 and miR-222 to downregulate the KIT oncogene, implying that these miRNAs contribute 
to cancer progression by regulating KIT expression.  
 
 
Table 1.3  Examples of microRNAs located in deleted, amplified or breakpoint regions commonly 
involved in human cancers. Adapted from143-146. 
 
 
 
 
Epigenetic alterations  
Epigenetic events, such as DNA methylation and histone modification, have also 
been linked to the deregulation of miRNA expression in cancer. In silico analyses has 
revealed that a significant proportion of miRNA gene promoters contain a CpG island.152, 153 
In addition, several groups have shown that DNA-demethylating agents and/or histone 
deactylase (HDAC) inhibitors upregulate the expression of miRNAs in cancer cells.139, 154, 155 
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A representative example is provided by the work of Saito et al.154 wherein 17 out of 313 
human miRNAs analysed were upregulated more than three-fold in bladder cancer cells upon 
treatment with chromatin modifying drugs. Of these miRNAs, miR-127 was the most 
differentially expressed and was found to be embedded in a CpG island.154 It was further 
shown that miR-127 acts as a tumour suppressor through BCL6 repression.154 On the other 
hand, miRNAs themselves can regulate DNA methylation by targeting components of the 
epigenetic machinery. For instance, it has been shown in both lung cancer and acute myloid 
leukaemia that miR-29 directly targets DNMT3A and -3B.156, 157 Enforced expression of miR-
29 in lung cancer cell lines restored normal patterns of DNA methylation, induced re-
expression of silenced tumour suppressor genes and inhibited tumourigenicity in vitro and in 
vivo.156 
 
Transcriptional regulation   
Transcriptional regulation is a crucial feature of the fine tuning of miRNA expression in 
cells. Although many miRNA-transcription factor relationships have been discovered in 
cancer, much attention has focused on the role of the proto-oncogene MYC in the regulation 
of miRNA expression. Deregulated expression or function of MYC is one of the most 
common features of human cancer.158 MYC was initially found to directly transactivate an 
oncogenic group of miRNAs known as the miR-17–92 cluster.159 The miR-17-92 cluster, 
which consists of six miRNAs co-transcribed from a locus on chromosome 13, is frequently 
amplified in B-cell lymphomas and solid malignancies.160, 161 Conversely, studies have 
revealed that MYC activation leads to widespread repression of a large group of miRNAs, 
several of which are known tumour suppressors such as let-7 family members, miR-15a/16-1 
and miR-34a.162, 163 Chang et al.162 revealed that much of this repression is likely to be a 
direct result of MYC binding to miRNA promoters. Reintroduction of MYC-repressed 
miRNAs was shown to markedly suppress tumourigenesis in vivo, supporting a central role 
for miRNA repression in the complex network of MYC-induced tumourigenesis.162 
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Defects in the miRNA biogenesis pathway 
Factors affecting miRNA processing have also been implicated in tumourigenesis. A 
comprehensive study headed by Kumar et al.164 demonstrated that impaired miRNA 
biogenesis promotes tumourigenesis in vivo though deregulation of specific oncogenes. 
Drosha and Dicer serve as key regulatory proteins in the miRNA processing pathway and 
their alterations have been observed in a number of cancers.164-166 Karube et al.165 found that 
a significant proportion of lung cancers have reduced expression levels of Dicer and this 
downregulation was associated with shortened postoperative survival. In breast cancer, Dicer 
expression is significantly downregulated in the more aggressive tumour types.166 
Corresponding to this, abnormalities of the long arm of chromsome 14, where Dicer is 
situated, has been reported in various cancers.167-170 Most recently it was shown that low 
Dicer and Drosha expression levels are significantly associated with survival in patients with 
ovarian cancer.171 Altogether, the current evidence suggests that defective miRNA processing 
may promote tumourigensis.  
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2 AIM OF MY STUDIES  
 
Gastric MALT lymphoma provides an outstanding model for studying multiple 
aspects of lymphoma development. In order to broadly improve our understanding of the 
pathogenesis of this disease at the molecular level, three main objectives were pursued in the 
course of my studies.   
  
• Determination of the specificity of gastric MALT lymphoma surface 
immunoglobulin. To address the issue of antigen receptor specificity we aimed to 
produce a panel of both human and murine recombinant MALT lymphoma-derived, 
surface-exposed tumour immunoglobulins. An ELISA approach could then be 
implemented to perform a comprehensive screen of antigen reactivity.   
 
• Elucidation of the role of infiltrating T cells in MALT lymphoma.  
In this study, the composition of T-cell subsets was assessed in order to determine the 
presence of regulatory T cells in the MALT lymphoma environment. We further 
endeavoured to address the impact of infiltrating T cells on tumour B-cell 
proliferation in vitro and on tumour development in vivo.  
 
• Investigation of miRNA deregulation in MALT lymphomagensis.  
Initially we set out to determine the unique miRNA expression profile associated with 
the development and progression of MALT lymphoma. Subsequently, we aimed to 
identify relevant tumour suppressor miRNAs in both low and high grade MALT 
lymphoma. Possible mechanisms causing deregulation of miRNA expression were 
also addressed in this project.  
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3 RESULTS 
 
Short summaries and reprints of publications and manuscripts describing the results 
obtained during my PhD. 
 
3.1 Gastric MALT lymphoma B-cells express polyreactive, somatically 
mutated immunoglobulins 
 
Authors: Vanessa J. Craig, Isabelle Arnold, Christiane Gerke, Minh Q. Huynh, Thomas 
Wundisch, Andreas Neubauer, Christoph Renner, Stanley Falkow and Anne 
Mueller 
 
Journal:  Blood, 21 January 2010, Vol. 115, No. 3, pp. 581-591. 
 DOI 10.1182/blood-2009-06-228015. 
 
 
 
Summary: This publication describes our efforts to characterise and determine the 
specificity of MALT lymphoma surface immunoglobulin. A panel of murine 
and human MALT lymphoma-derived immunoglobulins were cloned and 
recombinantly expressed. Sequence analysis revealed the majority of murine 
tumours were monoclonal, had undergone somatic hypermutation and more 
than half of all tumours showed evidence of intraclonal variation and positive 
and/or negative selective pressure. The recombinantly expressed MALT 
lymphoma antibodies exhibited a polyreactive binding profile in a series of 
ELISA assays. Auxiliary to this, a strong bias towards the use of VH gene 
segments often linked to auto- and/or polyreactive antibodies was found. 
Taken together, the results suggest that MALT lymphoma development may 
be facilitated by an array of local self and foreign antigens that provide direct 
antigenic stimulation of the tumour cells via their B-cell receptor.  
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3.2 B-cell receptor signalling and CD40 ligand-independent T cell help 
cooperate in Helicobacter-induced MALT lymphomagenesis 
 
Authors: Vanessa J. Craig, Sergio B. Cogliatti, Isabelle Arnold, Christiane Gerke, Jan 
Erik Balandat, Thomas Wundisch, Andreas and Anne Mueller 
 
Journal:  Leukemia, 29 April 2010, Vol. 24, pp. 1186–1196. 
 DOI: 10.1038/leu.2010.76 
 
 
 
Summary:  In order to assess the functional consequences of the polyreactive nature of 
MALT lymphoma B cells, transient ex vivo cultures of murine MALT 
lymphoma cells were established. Explanted tumour B-cells were found to 
proliferate upon stimulation with the same panel of self and foreign antigens 
that are recognised by their surface antibodies. We next set out to clarify the 
role of infiltrating T cells in the MALT lymphoma environment. The depletion 
of CD4+ and CD25+ T cells prevented the proliferation of tumour cells both ex 
vivo and in vivo. This pro-tumourgenic influence was independent from direct 
contact between the T and B cells via CD40/CD40L signalling. A significant 
proportion of tumour-infiltrating CD4+ T cells were found to be highly 
suppressive CD25+FoxP3+ regulatory T cells (Treg). These cells were actively 
recruited by the tumour cells through secretion of the Treg-attracting 
chemokines CCL17 and CCL22. In summary, our data suggest that B-cell 
receptor-derived signals cooperate with T-helper cell signals in driving the 
progression of MALT lymphoma, providing an explanation for the unique 
antigen dependence of this B-cell malignancy.  
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3.3 Epigenetic silencing of miRNA-203 dysregulates ABL1 expression 
and drives Helicobacter-associated gastric MALT lymphomagenesis 
 
Authors: Vanessa J. Craig, Sergio B. Cogliatti, Hubert Rehrauer, Thomas Wündisch 
and Anne Mueller 
  
 
Publication  
status:   Manusript submitted  
 
 
Summary:   Herein, we endeavored to define a novel molecular pathway involved in the 
pathogenesis of MALT lymphoma. The miRNA transcriptomes of MALT 
lymphomas and normal tonsil tissues were first compared at a genome-wide 
level. One miRNA, miR-203, was 11-fold downregulated in the lymphomas 
and was shown to be silenced due to CpG island promoter hypermethylation. 
Ectopic re-expression of miR-203 by transfection of Burkitt’s lymphoma cells 
or lentiviral transduction of primary murine MALT lymphoma cells was 
sufficient to prevent tumour cell proliferation in vitro. We further show here 
that the miR-203 target, ABL1, is over-expressed in MALT lymphoma 
compared to matched gastritis material from the same patients. In addition, 
proliferation of primary MALT lymphoma cells explanted from Helicobacter-
infected mice could be blocked by the tyrosine kinase inhibitors, imatinib and 
dasatinib. Finally, the treatment of tumour-bearing mice with imatinib induced 
MALT lymphoma regression in vivo. In summary, our results show that the 
progression from reactive gastritis to MALT lymphoma may be epigenetically 
regulated by miR-203 promoter methylation and ABL1 represents a novel 
target for the treatment of this malignancy.   
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Summary 
Gastric mucosa-associated lymphoid tissue lymphoma develops in the chronically 
inflamed mucosa of Helicobacter pylori-infected patients. MicroRNA expression profiling of 
human MALT lymphoma revealed an 11-fold down-regulation of miR-203, which resulted 
from promoter hypermethylation and coincided with the dysregulation of the miR-203 target 
ABL1. Demethylating treatment of lymphoma B-cells led to an increase in miR-203 
expression and concomitant ABL1 down-regulation. The lentiviral delivery of miR-203, as 
well as treatment with ABL inhibitors, prevented primary MALT lymphoma cell 
proliferation in vitro. Finally, the treatment of tumor-bearing mice with imatinib induced 
MALT lymphoma regression in vivo. Our results show that MALT lymphomagenesis is 
epigenetically induced by miR-203 promoter methylation and identify ABL1 as a novel 
target for the treatment of this malignancy.   
 
Significance 
Gastric MALT lymphoma represents an interesting paradigm of bacterially induced 
tumors. The molecular pathways involved in the clonal outgrowth of malignant B-cells from 
a background of chronic active Helicobacter-associated gastritis remain ill-defined. We show 
here that this process is epigenetically regulated, and involves the regulatory non-coding 
RNA miR-203 and its target ABL1. Using human material, various cell culture models and a 
mouse model of Helicobacter-induced lymphoma, we provide evidence that miR-203 is a 
bona fide tumor suppressor microRNA in the context of MALT lymphomagenesis and that 
its lentiviral reintroduction suppresses tumor cell proliferation in vitro. We further introduce 
ABL1 as a promising new target for MALT lymphoma treatment based on our finding that 
ABL inhibitors induce tumor regression in experimentally infected mice.   
 
Highlights 
-miR-203 is epigenetically regulated in MALT lymphoma by promoter hyper-methylation 
-lentiviral re-expression of miR-203 blocks primary MALT lymphoma cell proliferation  
-miR-203 exerts its tumor suppressive activity by repressing its target ABL1 
-inhibitors of ABL enzymatic activity prevent MALT lymphoma growth in vitro and in vivo 
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Introduction  
Mucosa-associated lymphoid tissue (MALT) lymphomas account for 8% of all non-
Hodgkin’s lymphomas (Thieblemont et al., 2005). The development of gastric MALT 
lymphoma is tightly linked to chronic infection with the human bacterial pathogen 
Helicobacter pylori (Isaacson and Du 2004); consequently, antibiotic eradication therapy is 
now the first line treatment for this malignancy (Bertoni et al., 2002, Bertoni and Zucca 
2002, Wundisch et al., 2005). MALT lymphomagenesis is initiated by H. pylori-associated 
chronic inflammation and the subsequent accumulation of gastric organized lymphoid tissue, 
from which individual neoplastic clones may grow out and invade the adjacent epithelium 
(Isaacson and Du 2004).  
 
We have shown recently that MALT lymphoma tumor immunoglobulins (Igs) are 
clonal, somatically hypermutated and polyreactive, i.e. they bind to a variety of unrelated 
self- and foreign antigens (Craig et al., 2010a). The same panel of antigens that are 
recognized by MALT lymphoma surface Igs induce proliferation of explanted tumor cells, 
supporting the notion that early low grade gastric MALT lymphoma is an antigen-dependent 
malignancy (Craig et al., 2010b). Low grade gastric MALT lymphomas are infiltrated by 
large numbers of T-cells, which are polarized to produce Th2 cytokines such as interleukin-4 
(Knorr et al., 1999; Mueller et al., 2005). The depletion of T-cells prevents the proliferation 
of tumor cells ex vivo and induces tumor regression in a mouse model of gastric MALT 
lymphoma (Craig et al., 2010b), implying a synergistic role for T-cell-derived signals and B-
cell receptor-mediated antigen recognition during early MALT lymphoma pathogenesis.   
  
MicroRNAs (miRNAs) are well-conserved, 18-25 nucleotide long non-coding RNAs 
with pivotal roles in post-transcriptional gene regulation (Ambros et al., 2004). miRNA 
expression patterns correlate with particular cancer types (Lu et al., 2005) and are predictive 
of clinical outcome (Calin et al., 2005; Yanaihara et al., 2006). Over 50% of miRNA genes 
are located in cancer-associated genomic regions (Calin et al., 2004). Many miRNAs are 
known to function as tumor suppressors, regulating the expression of oncoproteins such as 
RAS (Johnson et al., 2005) and c-MYC (O’Donnell et al., 2005). Here, we demonstrate that 
miR-203 is down-regulated in gastric MALT lymphoma due to promoter hypermethylation. 
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The ectopic re-expression of miR-203 in primary MALT lymphoma cells down-regulates the 
expression of the miR-203 target ABL1 and blocks tumor cell proliferation in vitro. Finally, 
inhibition of ABL1’s tyrosine kinase activity by imatinib blocks MALT lymphoma cell 
proliferation ex vivo and prevents tumor formation in mice, suggesting for the first time an 
important oncogenic role for ABL1 in the pathogenesis of B-cell tumors not harboring the 
t(9;22) chromosomal translocation fusing the bcr and abl1 genes.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
  69 
 
Results 
The expression of miR-203 and of its target ABL1 is dysregulated in MALT lymphoma 
In order to identify miRNAs that are differentially expressed in human Helicobacter-
associated MALT lymphoma compared to normal lymphoid tissue, we generated array-based 
expression profiles for five low-grade MALT lymphoma and four tonsil samples that 
included all 795 currently annotated human mature miRNAs. Of the 157 miRNAs exhibiting 
high variation across the nine samples, six were strongly down-regulated in all cases of 
lymphoma, but in none of the tonsil samples (Figure 1A, Supplemental Table 1). We focused 
on miR-203, which was downregulated by ~11 fold in the lymphomas and has previously 
been implicated in tumor suppression (Bueno et al., 2008). Its dysregulation could be 
confirmed by quantitative (q)PCR in the samples used for expression profiling as well as in 
an independent set of archived cases of Helicobacter-associated gastritis and gastric MALT 
lymphoma (Figure 1B,C). As miR-203 is known to regulate ABL1 (Bueno 2008), we 
assessed ABL1 expression in eight cases of gastric MALT lymphoma for which matched 
gastritis material was available. qPCR analysis revealed that seven of the eight lymphoma 
samples exhibited higher ABL1 expression than the corresponding gastritis (Figure 1D). 
Similar patterns of inverse miR-203 and ABL1 expression were detected in four matching 
pairs of gastric lymphoma and corresponding gastritis harvested from Helicobacter-infected 
BALB/c mice (Figure 1E,F). In summary, miR-203 and its target ABL1 are differentially 
regulated in human gastric lymphoma as well as in a mouse model of the disease, implying 
ABL1 as a possible target of miR-203 in MALT lymphomagenesis. 
 
The miR-203 promoter is specifically hypermethylated in MALT lymphoma 
The promoter region of the miR-203 genomic locus contains a CpG island flanking 
the transcriptional start site (Figure 2A), which has been shown to be hypermethylated in 
certain hematological malignancies and hepatocellular carcinoma (Bueno et al., 2008; Furuta 
et al., 2009). We determined the methylation status of the miR-203 promoter in several cases 
each of normal human tonsil, gastritis and low as well as high grade gastric MALT 
lymphoma by sodium bisulfite genomic sequencing. The miR-203 promoter region was 
heavily methylated in the majority of independent clones analyzed of all low and high-grade 
MALT lymphoma samples, but was largely unmethylated in the tonsil and gastritis tissues 
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(Figure 2B). In conclusion, the miR-203 promoter appears to be specifically hypermethylated 
in MALT lymphoma, which may lead to silencing of the genomic locus and may contribute 
to MALT lymphomagenesis. 
 
The expression of miR-203 is epigenetically regulated and controls ABL1 levels and 
lymphoma cell proliferation in vitro 
To determine whether promoter methylation indeed affects miR-203 transcription, 
and as a consequence, ABL1 expression, we took advantage of a non-Hodgkin’s lymphoma 
cell line exhibiting a degree of miR-203 promoter methylation that is comparable to that 
found in human MALT lymphoma (BL2; Figure 3A). The treatment of BL2 cells with the 
DNA-demethylating agent 5'-azacytidine (Aza), either alone or in combination with the 
histone deacetylase inhibitor 4-phenylbutyric acid (PBA), resulted in decreased miR-203 
promoter methylation and a concomitant rise in miR-203 expression (Figure 3A,B); the 
expression of ABL1 was inversely correlated with miR-203 at the mRNA and protein levels 
(Figure 3C,D). The combined treatment with both compounds resulted in a more efficient 
drop in promoter methylation and a greater increase in miR-203 expression, but did not 
further reduce ABL1 expression (Figure 3A-D). To confirm directly that miR-203 targets 
ABL1, pre-miR-203 precursor molecules were introduced into BL2 cells by electroporation. 
The ectopic expression of pre-miR-203 led to a significant down-regulation of ABL1 
expression at both the mRNA and the protein levels as compared to a scrambled negative 
control pre-miR (Figure 3E,F) and blocked the proliferation of BL2 cells as determined by 
[3H] thymidine incorporation (Figure 3G). The combined results suggest that miR-203 is 
epigenetically regulated and acts as a tumor suppressor miRNA through its effects on ABL1 
expression.  
 
The proliferation of MALT lymphoma cells is blocked by imatinib in vitro and in vivo 
To assess the effects of miR-203 delivery on primary murine MALT lymphoma cells, 
we generated lentiviral particles carrying a miR-203-encoding expression vector and 
transduced primary murine gastric MALT lymphoma cells isolated from BALB/c mice that 
had been infected with H. felis for 18 months. The lentiviral delivery of miR-203 to 
explanted murine MALT lymphoma cells resulted in increased miR-203 levels, decreased 
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ABL1 expression and a concomitant block in the Helicobacter antigen-dependent 
proliferation of the cells (Figure 4A-C). These observations raised the possibility that ABL 
inhibitors such as imatinib (Gleevec) might prevent the proliferation of primary MALT 
lymphoma cells in vitro and in vivo. Indeed, addition of imatinib to the primary cell cultures 
efficiently blocked their proliferation in a dose-dependent manner (Figure 4D); similar 
results were obtained with the ABL inhibitor dasatinib (Figure 4D). Tumor cells that had 
spread to the spleen were equally sensitive to ABL inhibition as cells derived from the 
primary gastric tumor (Figure 4E). To assess a possible therapeutic effect of imatinib in a 
preclinical model of Helicobacter-induced MALT lymphoma, BALB/c mice were infected 
for 15 months with H. felis to allow for lymphoma development. A group of mice received 
imatinib via the drinking water for another three months while all other mice remained 
untreated. Whereas between 2 to 15 tumors had formed in the majority of control mice, all 
imatinib-treated mice were tumor free as assessed macroscopically and histopathologically at 
the 18 month post infection endpoint of the study (Figure 4F,G). Imatinib had no effect on H. 
felis colonization densities (Figure 4H), ruling out a direct effect of the treatment on the 
underlying infection. The combined results suggest that miR-203 re-expression in murine 
primary MALT lymphoma cells prevents their proliferation and that this effect is mediated 
by the tyrosine kinase activity of the miR-203 target ABL1 in vitro and in vivo.   
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
  72 
 
Discussion  
Our array-based miRNA transcriptome analysis identified miR-203 as one of the 
most strongly down-regulated miRNAs in gastric lymphoma compared to normal lymphoid 
tissue; its dysregulation could be attributed to extensive promoter hypermethylation. Our 
results further suggest that the loss of miR-203 expression and the resulting dysregulation of 
its target ABL1 contribute directly to gastric lymphomagenesis and identify ABL1 as a new 
target in the treatment of this malignancy. Several previous reports have indicated a tumor 
suppressive role for miR-203. It is encoded on a fragile 7Mb region of murine chromosome 
12 that encodes ~12% of all genomic miRNAs and that is frequently deleted in hematopoietic 
malignancies (Bueno et al., 2008). Its expression is downregulated in cancers of the liver 
(Ladeiro et al., 2008), central nervous system (Gaur et al., 2007) and in some types of 
leukemia (Bueno et al., 2008). Experimental inhibition of miR-203 enhances the growth of 
lung carcinoma cells (Cheng et al., 2005) and the restoration of miR-203 levels significantly 
reduces the proliferation of hepatocellular carcinoma (Furuta et al., 2009), certain leukemias 
such as chronic myelogenous leukemia (CML) (Bueno et al., 2008) and head and neck 
squamous cell carcinoma (Lena et al., 2008).  
 
MALT lymphomas are negative for the Philadelphia chromosome (Ph-, data not 
shown), i.e. they do not harbor the t(9;22) reciprocal translocation fusing the BCR and ABL1 
gene loci that is a hallmark of CML and of a subset of acute lymphoblastic leukemias (ALL) 
(Ottmann and Wassmann 2005). However, we found that ABL1 is significantly more 
strongly expressed in human MALT lymphoma biopsies than in corresponding gastritis 
material from the same patient. The treatment of BL2 cells (which are also Ph- and harbor a 
methylated miR-203 promoter region) with demethylating agents and consequent re-
expression of miR-203 repressed cellular ABL1 levels and reduced BL2 proliferation, 
showing that miR-203 can function as a tumor suppressor independently of the t(9;22) 
translocation.  
 
ABL1 is predominantly expressed in the hematopoietic system, in particular in 
lymphocytes; targeted deletion or mutation of ABL1 in mice results in splenic and thymic 
atrophy and lymphopenia as well as an increased susceptibility to infections (Schwartzberg et 
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al., 1991). In B-cells, ABL1 functions in B-cell receptor signaling, probably by directly 
interacting with, and phosphorylating, the BCR co-receptor CD19 (Zipfel et al., 2000). ABL1 
overexpression has been associated with Ph- hematopoietic malignancies such as chronic 
lymphocytic leukemia (CLL) (Lin et al., 2006). In CLL, ABL1 overexpression has been 
linked to constitutively active BCR signaling and NF-κB activation (Lin et al., 2006), i.e. to a 
signaling pathway that is known to contribute to MALT lymphomagenesis (Isaacson and Du 
2004).  
 
We have shown recently that BCR signaling synergizes with T-cell-derived signals to 
drive MALT lymphoma cell proliferation (Craig et al., 2010b). Inhibition of ABL1 
expression by miR-203 replacement or inhibition of its tyrosine kinase activity would 
therefore be predicted to block the Helicobacter-induced proliferation of primary MALT 
lymphoma cells. Indeed, the lentiviral delivery of miR-203 or treatment of explanted murine 
MALT lymphoma cells with the tyrosine kinase inhibitor imatinib efficiently prevented their 
proliferation. The treatment of Helicobacter-infected mice prevented MALT 
lymphomagenesis in vivo, suggesting that ABL inhibition might be a valid strategy for the 
treatment of patients that are refractory to eradication therapy. In addition to its beneficial 
effects in patients with CML (Baselga et al., 2006), imatinib has recently shown promise in 
adult patients with Ph+ B-cell ALL (Ottmann and Wassmann 2005) and has been proposed 
for the treatment of Ph- CLL patients overexpressing ABL1 (Lin et al., 2006).    
  
In summary, we show here that the progression from reactive, Helicobacter-
associated gastritis to low grade MALT lymphoma is likely to be epigenetically regulated 
through methylation of the miR-203 promoter region. Transcriptional repression of miR-203 
results in dysregulation of ABL1, which in turn drives MALT lymphoma cell proliferation. 
Our results identify ABL1 as a promising new target for the treatment of low grade MALT 
lymphoma, in particular of the ~20% of patients who are refractory to eradication therapy as 
a first line treatment of the disease. 
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Experimental procedures 
 
Patient material  
Human patient material was obtained from eight patients with H. pylori-positive, 
t(11;18)(q21:q21)-negative gastric low grade MALT lymphoma that were part of a 
previously published study conducted at Philipps-University Hospital Marburg, Germany 
(Huynh et al., 2008). miRNA expression analysis was performed on fresh and archived cases 
of H. pylori-positive gastritis, H. pylori-positive gastric low or high grade MALT lymphoma 
and tonsil material drawn from the surgical pathology files of the Institute of Pathology at the 
Cantonal Hospital St. Gallen, Switzerland. All data were blinded to guarantee patients' 
protection and were generated in agreement with the guidelines for use of human material in 
research issued by the participating Institutions’ Ethics Committees.  
 
Animal experimentation, cell culture, nucleoporation and lentivirus infection   
Female BALB/c mice were infected intragastrically at six weeks of age with 5x107 H. 
felis (CS1, ATCC 49179). All procedures were approved by the Zurich cantonal veterinary 
office. Mice received 75mg/kg per day imatinib in their drinking water for the final 3 months 
of an 18 month infection experiment. After 18 months, macroscopically visible gastric 
tumors were collected, single cell suspensions were generated and cultured for 3 days in 
RPMI/10 % FCS with 10 µg/ml Helicobacter lysate and 0.01-30 µM imatinib or dasatinib 
(generously provided by Novartis, Basel, Switzerland and C. Nevado, Institute of Organic 
Chemistry, University of Zurich, respectively). Tumor cell proliferation was quantified by 
[3H] thymidine incorporation. For DNA demethylation, BL2 cells were treated with 5 µM 5'-
azacytidine and/or 3 mM 4-phenylbutyric acid (both from Sigma-Aldrich). For the purpose 
of miR-203 re-expression, 1x106 BL2 cells were nucleoporated using an Amaxa 
Nucleoporator (Gaithersburg, MD) with miR-203 precursor or negative control 
oligonucleotides (both from Ambion, Austin, TX) and harvested 48 hours later for ABL1 
expression analysis by qRT-PCR or Western Blot as described in the supplemental methods. 
Primary MALT lymphoma cells were transduced with lentiviral particles harboring a miR-
203 expression construct (Systems Biosciences, Mountain View, CA) in the presence of 8 
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µg/ml polybrene by spinoculation. The production of lentiviruses and the transduction 
protocol is described in the supplemental methods. 
 
Microarray-based miRNA expression profiling and bisulfite genomic sequencing 
Microarray experiments were performed using the Agilent Human miRNA 
Microarray Kit version 10.0. as described in detail in the supplemental methods. 
Normalization and statistical analysis was performed using the quantile normalization 
implemented in the package PreprocessCore and the package genefilter, respectively. All raw 
data of the microarray experiments are publicly accessible under the accession number 
GSE23877 (http://www.ncbi.nlm.nih.gov/geo/). The procedures used for determination of the 
miR-203 promoter methylation status are described in the supplemental methods. 
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Figure 1. miR-203 and its target ABL1 are dysregulated in MALT lymphoma.  
(A) Heatmap representation of 157 miRNAs with a standard deviation of log2 expression 
>0.05 across the four tonsil and five MALT lymphoma samples analyzed on Agilent miRNA 
microarrays; six consistently down-regulated miRNAs are annotated. (B) Validation of miR-
203 expression of the samples shown in A as assessed by LNA qRT-PCR. miR-203 levels 
were normalized to U6 snRNA expression. (C) Expression levels of miR-203 in human 
gastritis and MALT lymphoma FFPE tissue samples as determined by LNA qRT-PCR. (D) 
ABL1 expression in MALT lymphoma and corresponding gastritis material derived from 
eight patients. ABL1 transcript levels were quantified by qRT-PCR and normalized to 
GAPDH expression. (E,F) miR-203 and ABL1 expression in four pairs of murine MALT 
lymphomas and corresponding gastritis harvested from 18 month infected BALB/c mice.   
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Figure 2. The miR-203 promoter is specifically hypermethylated in MALT lymphoma. 
(A) Schematic representation of the miR-203 gene embedded in a CpG island showing the 
393 bp region analyzed for methylation status. The position of the miR-203 gene is indicated 
by a triangle. The transcription start site is represented by a bent arrow. (B) Bisulfite 
sequencing of the upstream region of miR-203 in human tonsil, gastritis and low and high 
grade MALT lymphoma samples. 3-4 representative samples are shown for each tissue type 
and 3 single clones are represented for each individual sample. Black and white circles 
represent methylated and unmethylated CpG, respectively. All 61 sequenced CpGs are 
indicated.  
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Figure 3. The expression of miR-203 is regulated epigenetically and controls ABL1 
expression and lymphoma cell proliferation. (A) miR-203 promoter methylation in BL2 
cells as determined by bisulfite sequencing. Cells were either treated with 5 µM 5'-
azacytidine, alone or in combination with 3 mM 4-phenylbutyric acid, or left untreated. 3 
single clones were sequenced for each treatment and the percentage of methylated CpG 
dinucleotides is shown. Black and white circles represent methylated and unmethylated CpG. 
(B,C) qRT-PCR analysis of miR-203 and ABL1 transcript in BL2 cells with and without 
drug treatment. (D) ABL1 protein levels of the experiment outlined in A-C as assessed by 
Western blot analysis with α-tubulin serving as a loading control.  (E) Normalized ABL1 
expression of BL2 cells transfected with either miR-203 precursor molecules (miR-203) or 
negative control precursor molecules (N/C) at 50 nM or 100 nM final concentration. (F) 
ABL1 protein levels of the experiment described in E as assessed by Western blot analysis 
with α-tubulin serving as loading control.  (G) The proliferation of cells transfected as 
described in E as determined by [3H] thymidine incorporation.  
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Figure 4. miR-203 replacement and  pharmacological ABL inhibition block MALT 
lymphoma growth in vitro and in vivo. (A-C) Primary murine MALT lymphoma cells were 
transduced with lentiviruses carrying a pre-miR-203-expressing or empty vector. miR-203 
and ABL1 expression were assessed by qRT-PCR; the proliferation of transduced cells was 
determined by [3H] thymidine incorporation with or without stimulation with H. felis 
sonicate. (D,E) [3H] thymidine incorporation of gastric (D) and splenic (E) primary murine 
MALT lymphoma cells stimulated with H. felis sonicate and treated with increasing 
concentrations of imatinib or dasatinib as indicated. Unstimulated cells are included for 
comparison. Vertical bars indicate standard deviations. (F) Gastric MALT lymphoma 
formation in female BALB/c mice infected for 18 months with H. felis. One group received 
imatinib through the drinking water for months 16-18 of the experiment. Macroscopically 
visible tumors >1mm in diameter are plotted. (G) Representative micrographs of H&E-
stained sections of the mice shown in F. Scale bar indicates 50 µm. (H) H. felis colonization 
as determined by flaB-specific qPCR of the mice shown in F. 
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Supplemental methods 
 
miR-203 and ABL1 expression analysis 
Expression of mature miR-203 was analyzed using the miRCURY locked nucleic 
acid (LNA) microRNA PCR system following the manufactures’ protocol (Exiqon). Briefly, 
10 ng of total RNA was subjected to cDNA synthesis using miR-203 or U6 snRNA-specific 
primers. The cDNA template was diluted 1:10 and real time PCR reactions were performed 
following the manufactures’ recommendations (LightCycler; Roche, Basel, CH). 
Calculations of miRNA expression levels were performed using the comparative ΔΔCt 
method and normalized against U6 snRNA levels. ABL1-specific real time RT-PCR 
(LightCycler; Roche, Basel, CH) was performed with the LightCycler 480 SYBR Green I 
master kit (Roche). GAPDH transcript levels were determined for normalization. Human and 
murine ABL1 primers were published previously (Alvarez et al. 2004; Sun et al., 2001). 
Protein extracts were made using either RIPA cell lysis buffer (50 mM Tris-HCl [pH7.5], 1% 
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1 mM PMSF) or 
2x Laemmli sample buffer (4% SDS, 20% glycerol, 120 mM Tris [pH 6.8]). Proteins were 
separated by SDS/polyacrylamide gel electrophoresis and transferred onto nitrocellulose 
membranes. Membranes were probed with antibodies against ABL1 (BD Biosciences, CA, 
USA) and α-tubulin (Sigma-Aldrich, St. Louis, MO).  
 
DNA methylation analysis of the miR-203 promoter 
Specific oligonucleotides for bisulfite sequencing of the miR-203 CpG island were 
described previously (Bueno et al. 2008). Genomic DNA was isolated from FFPE tissue or 
fresh material using the RecoverAll total RNA Isolation kit (Ambion, Streetsville, Canada) or 
the Quiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA), respectively. gDNA 
(2µg) was converted with sodium bisulfite as previously reported (Frommer et al.1992) 
Following amplification of the bisulfite-converted DNA, the methylation status was assessed 
by sequencing the miR-203 bisulfite converted promotor region. 
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Lentivirus production and infection  
The pre-mir-203 lentiviral expression construct used to re-express mature mir-203 in 
murine primary lymphoma cells was purchased from Systems Biosciences (Mountain View, 
CA). Third-generation lentiviral vector packaging constructs were generously provided by 
Stefano Ferrari at our Institute and consisted of the three plasmids pMDLg/pRRE, pHCMV-
G and pRSVrev. The pre-mir-203 expression vector (2.5 µg) was transfected along with the 
lentivirus packaging plasmids (2.5 µg of each plasmid) into HEK293T cells and the 
supernatent was collected 48 and 72 hours after transfection. Primary lymphoma cells were 
incubated with the viral particles. Empty lentivirus was used as a control for the experiments. 
H. felis stimulated primary MALT lymphoma cells were transduced in the presence of 
polybrene (8 µg/mL) by spinoculation in a centrifuge at 700 x g for 90 minutes at room 
temperature in a 96-well plate. 72 hours following infection, tumor cell proliferation was 
quantified by [3H] thymidine incorporation assay. Expression of mature mir-203 was 
validated by real-time PCR. 
 
Microarray-based miRNA expression profiling and bisulfite genomic sequencing 
Total RNA (including miRNA) was extracted from fresh frozen and FFPE biopsy 
samples (three 20 μm slices) using the RecoverAll total RNA Isolation kit (Ambion, 
Streetsville, Canada). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). miRNA microarray experiments were 
performed using the Agilent Human miRNA Microarray Kit version 10.0. For each sample, 
100 ng total RNA were hybridized with the miRNA array and further processed according to 
the Agilent's miRNA Microarray System protocol. The arrays were scanned with an Agilent 
Technology G2565B scanner (Agilent Technologies, Palo Alto, CA). The scanned images 
were gridded and analysed using Agilent Feature Extraction Software version 9.5. 
Normalization and statistical analysis was performed with R/Bioconductor. Specifically, we 
used the quantile normalization implemented in the package PreprocessCore and ran the 
statistical test using the package genefilter. 
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Indeed, MYC overexpression was more stongly correlated with gDLBCL than 
low grade MALT lymphoma cases and the re-expression of certain MYC-
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Abstract 
Gastric marginal zone B-cell lymphoma of MALT arises in the context of chronic 
inflammation induced by the bacterial pathogen Helicobacter pylori. Such low grade 
lymphoma may progress by acquiring one of several characteristic chromosomal 
translocations or by transforming into high grade gastric diffuse large B-cell lymphoma 
(gDLBCL). The mechanism of malignant transformation remains poorly understood. By 
comparing microRNA expression profiles of low and high grade gastric lymphoma cases we 
have identified a signature of ~25 dysregulated microRNAs that share the characteristic of 
being transcriptionally repressed by Myc. Correspondingly, Myc over-expression was 
detected in 80% of high grade, but only 20% of low grade lymphomas spotted on a tissue 
microarray. The siRNA-mediated knock-down of Myc blocked proliferation of DLBCL cell 
lines. Of the Myc-repressed miRNAs downregulated in malignant lymphoma, miR-34a 
showed the strongest anti-proliferative properties when overexpressed in DLBCL cell lines. 
We could further attribute miR-34a’s tumor suppressive effects to dysregulation of its target 
FoxP1. FoxP1 over-expression was detected in gDLBCL, but not in low grade lymphoma; 
FoxP1 knock-down efficiently blocked DLBCL proliferation. In conclusion, our results 
elucidate a novel Myc- and FoxP1-dependent pathway of transformation and suggest miR-
34a replacement therapy as a promising strategy in lymphoma treatment.  
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Introduction 
Gastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue 
(MALT) lymphomas are low grade extranodal B-cell lymphomas that arise in the context of 
chronic gastric inflammation induced by persistent Helicobacter pylori infection (Parsonnet 
et al., 1994). In its early stages, MALT lymphoma is an indolent and localized disease that 
can be treated by antibiotic eradication therapy targeting the underlying infection (Isaacson 
and Du, 2004). In line with the concept that gastric MALT lymphomas are antigen-driven 
tumors, the surface immunoglobulins of MALT lymphoma B-cells are clonal, somatically 
hypermutated, and have undergone positive selection (Qin et al., 1995). We have shown 
recently that MALT lymphoma tumor immunoglobulins (Igs) are polyreactive, i.e. they bind 
with similar affinity to various unrelated self and foreign antigens, and show a biased use of 
Ig VH gene segments previously linked to poly- and autoreactive antibodies (Craig et al., 
2010a). Early MALT lymphomas further require T-cell help in the form of soluble T-helper 
cell-derived signals, most likely B-cell mitogenic cytokines such as IL4 and IL5 (Craig et al., 
2010b).  
 
Low grade MALT lymphomas may progress either through the acquisition of one of 
three characteristic chromosomal translocations resulting in the constitutive activation of the 
NF-κB signaling pathway (Isaacson and Du, 2004), or through the histologically evident 
transformation into high-grade gastric diffuse large B-cell lymphoma (gDLBCL) (Chan et 
al., 1990; Peng et al., 1997). Such high grade transformation of Helicobacter-associated 
MALT lymphoma accounts for the majority of gDLBCL cases, whereas primary gDLBCL is 
rare (Chan et al., 1990; Peng et al., 1997). gDLBCL is characterized by antigen-independent 
growth, resistance to Helicobacter eradication therapy and a number of genetic alterations 
that may contribute to high grade transformation (Starostik et al., 2002). In particular, TP53 
mutations (Du et al., 1995), Bcl6 overexpression (Omonishi et al., 1998) and the aberrant 
DNA hypermethylation of tumor suppressor genes (Kondo et al., 2009) have been shown to 
be associated with high grade transformation. However, the precise molecular mechanisms 
underlying the transition from low-grade MALT lymphoma to gDLBCL remains largely 
unclear.  
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MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs, which 
modulate the expression of their target genes at the post-transcriptional level. Aberrant 
expression of specific miRNAs has been associated with both solid and hematopoietic 
malignancies (Lu et al., 2005), including chronic lymphocytic leukemia (Calin et al., 2004a), 
lung cancer (Calin and Croce, 2006; Yanaihara et al., 2006) and ovarian cancer (Calin et al., 
2004b; Zhang et al., 2008). The majority of human miRNAs are located at fragile sites or 
cancer associated genomic regions (Calin et al., 2004b). For example, the frequent down-
regulation of the fragile region encoding mir-15a and mir-16-1 promotes CLL through 
dysregulation of the Bcl2 oncogene (Calin et al., 2004a). The widespread deregulation of the 
miRNA transcriptome appears to be a hallmark of cancer and has been attributed to 
deletions, amplifications or mutations of miRNA loci (Calin et al., 2004b; Zhang et al., 
2008), epigenetic silencing (Saito et al., 2006), or the aberrant transcriptional regulation of 
miRNA genes (Zhang et al., 2008). Several studies have revealed the potential of miRNA 
expression profiles as diagnostic and prognostic markers of cancers (Yanaihara et al., 2006), 
which may be more useful than expression analysis of protein-coding genes for the 
classification and stratification of cancer subtypes (Lu et al., 2005).  
 
Here, we have used a microarray approach to identify miRNAs that are differentially 
regulated in gastric low grade MALT lymphoma and its transformed high grade disease 
counterpart. Interestingly, we found that a characteristic set of Myc-repressed miRNAs was 
down-regulated in the high grade, but not the low grade cases studied. Aberrant Myc 
expression indeed correlated with high grade transformation as analyzed 
immunohistochemically using a gastric lymphoma tissue microarray. Bioinformatic target 
prediction combined with functional analyses revealed that one of the miRNAs found to be 
down-regulated in high grade gDLBLC, miR-34a, represents a bona fide tumor suppressor 
miRNA in gastric lymphoma. MiR-34a acts through post-transcriptional control of its direct 
target FoxP1, a hematopoietic oncoprotein overexpressed in gDLBCL. In conclusion, our 
findings identify a new mechanism that links the aberrant expression of Myc and the 
resulting repression of the tumor suppressor miRNA miR-34a to FoxP1 deregulation in high 
grade transformation of gastric B-cell lymphoma. 
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Results and Discussion 
 
Myc-repressed miRNAs are specifically down-regulated in high grade-transformed 
gastric lymphoma  
To obtain global miRNA expression signatures of gDLBCL and its precursor lesions, 
total RNA isolated from 7-8 cases each of Helicobacter-associated reactive gastritis, low 
grade MALT lymphoma and high grade gDLBCL was hybridized to Agilent miRNA 
microarrays representing 795 human mature miRNAs. Unsupervised hierarchical clustering 
analysis revealed a clear segregation of the gDLBCL cases from the low grade MALT 
lymphomas and the gastritis samples (Figure 1A). The segregation of the latter two disease 
entities was incomplete (Figure 1A), reflecting the relative biological similarity of gastritis 
and low grade lymphomas. Statistical analysis of the dataset revealed only 25 differentially 
expressed miRNAs between these two groups (p<0.05; suppl. Table 1), whereas 88 miRNAs 
exhibited significant differences in expression between low and high grade lymphomas 
(suppl. Table 2).  
 
In order to identify miRNAs with a putative tumor suppressive role in high grade 
transformation, we focused on the subset of 57 miRNAs that were down-regulated in high 
grade, but not low grade tumors (Figure 1A). Interestingly, a large fraction of the down-
regulated miRNAs had previously been reported to be repressed by the Myc transcription 
factor (Chang et al., 2008). In fact, we found that of the 24 known human Myc-repressed 
miRNAs, 21 were down-regulated by at least 1.6- and up to 8.7 fold in high grade vs. low 
grade gastric lymphomas. The differential expression of two selected miRNAs, let-7 and 
miR-34a, was verified on the same panel of samples by locked nucleic acid (LNA) real time 
RT-PCR (Figure 1B,C). In conclusion, we found using whole-genome based miRNA 
expression profiling that high grade transformation of gastric MALT lymphoma is 
accompanied by a characteristic signature of repressed miRNAs, a substantial number of 
which are encoded by known target genes of Myc. 
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Myc is over-expressed in high grade gastric DLBCL and controls DLBCL proliferation 
in vitro  
Having obtained indirect evidence of Myc expression in gDLBCL, but not low grade 
MALT lymphoma, we next aimed to assess the Myc expression status of a set of 37 
gDLBCL and 39 low grade lymphomas spotted onto a gastric lymphoma tissue microarray 
(Bernasconi et al., 2008). Indeed, 80% of gDLBCL, but only 20% of low grade lymphomas 
showed high expression of Myc (Figure 2A,B), indicating that Myc expression may be a 
useful marker for the differential diagnosis of both disease entities. To assess a possible 
causal link between Myc expression and miRNA down-regulation in DLBCL, we transiently 
knocked down Myc expression in two DLBCL lines, of which one had the characteristics of 
the ‘activated B-cell’ type of DLBCL (‘ABC’; U2932) and the other had typical ‘germinal 
center’ type features (‘GC’, SUDHL4). The transient knock-down of Myc indeed increased 
expression of both let-7 (Figure 2C) and miR-34a (Figure 2D) in both cell lines in relation to 
a scrambled siRNA. Interestingly, the proliferation of both cell lines as determined by [3H] 
thymidine incorporation was significantly reduced upon siRNA-mediated Myc knock down 
(Figure 2E,F), indicating that Myc expression drives lymphoma cell proliferation, possibly 
via down-regulation of tumor suppressive miRNAs. 
 
To determine which of the Myc-repressed miRNAs have tumor suppressive 
properties in DLBCL cell lines in vitro, we focused on a panel of six miRNAs that were 
consistently predicted by both the TargetScan and PicTar algorithms to target known or 
putative hematopoietic oncogenes such as Bcl6, Ezh2, FoxP1 and Pax5. We introduced 
synthetic, chemically modified double-stranded precursor molecules of the six miRNAs (so-
called pre-miRs™) into U2932 and SUDHL4 cells by nucleoporation, either alone or in 
combination (Figure 2G,H). While all miRNAs on our panel had suppressive effects on 
tumor cell proliferation in relation to an unspecific negative control miRNA, one candidate, 
miR-34a, was particularly effective in this respect (Figure 2G,H). miR-34a is a known tumor 
suppressor miRNA in prostate and lung cancer and is a lead candidate for miRNA 
replacement therapy for the treatment of these malignancies (Wiggins et al., 2010). In 
conclusion, our combined bioinformatic and experimental approach identified a miRNA with 
interesting tumor suppressive characteristics in DLBCL in vitro.  
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miR-34a targets the transcription factor FoxP1 in DLBCL 
Bioinformatically predicted targets of miR-34a include the transcription factors Bcl6 
and FoxP1, which harbor one and two putative miR-34a seed regions in their 3’ untranslated 
region (UTR), respectively. As both have previously been linked to the pathogenesis of 
gDLBCL (Chen et al., 2006; Starostik et al., 2002), we aimed to test their possible post-
transcriptional regulation by miR-34a in the DLBCL cell lines introduced earlier. 
Quantitative RT-PCR of FoxP1 and Bcl6 expression after nucleoporation of U2932 and 
SUDHL4 cells with pre-miR-34a revealed that FoxP1, but not Bcl6, is a likely direct target 
of this miRNA (Figure 3A and data not shown). Protein levels of FoxP1 were also strongly 
reduced upon introduction of miR-34a into U2932 cells (Figure 3B). In order to measure a 
direct effect of miR-34a binding to its seed regions in the foxp1 gene, we cloned the wild 
type sequence of the seed region, or a mutant version in which four of the six positions had 
been mutated, downstream of a luciferase reporter gene. Co-transfection of pre-miR-34a with 
the luciferase expression vector harboring the wild type seed region, but not the mutant 
version, blocked reporter gene expression as assessed by luciferase activity assay (Figure 
3C). Interestingly, siRNA-mediated knock-down of Myc was as efficient as pre-miR-34a 
introduction in inhibiting FoxP1 expression (suppl. Figure 1). In summary, our results are in 
line with a recent report showing that miR-34a directly regulates FoxP1 expression by 
binding to at least one of its two predicted seed regions in the FoxP1 3’UTR (Rao et al 2010), 
and demonstrate that FoxP1 is a target of miR-34a and (an indirect target) of Myc in DLBCL 
cell lines. Our data further extend a previous report linking high FoxP1 expression to poor 
clinical outcome and a high risk of malignant transformation in MALT lymphoma patients 
(Sagaert et al., 2006). 
 
The miR-34a target FoxP1 is a bona fide oncoprotein in DLBCL 
As FoxP1 is a direct target of miR-34a, we asked whether FoxP1 is differentially 
expressed in gDLBCL and low grade MALT lymphoma. Indeed, a majority of gDLBCL, but 
very few of the low grade lymphoma cases spotted onto our tissue microarray showed 
reactivity with a FoxP1-specific antibody (Figure 4A,B). Interestingly, all FoxP1-positive 
cases also expressed Myc, irrespective of whether they were classified as low grade or high 
grade lymphomas. On the other hand, FoxP1 expression did not overlap with expression of 
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Bcl6, which is often used to distinguish between ‘GC’ and ‘ABC’ type DLBCL: similar 
proportions of FoxP1-positive cases were Bcl6-positive and –negative (data not shown). We 
postulated that the siRNA-mediated knock down of FoxP1 should have similar anti-
proliferative effects in DLBCL cell lines as the delivery of miR-34a. This was indeed the 
case: knock down of FoxP1 by ~64% (suppl. Figure 2) blocked the proliferation of four ‘GC’ 
and ‘ABC’ type DLBCL cell lines at similar levels, and roughly as efficiently as the 
reintroduction of miR-34a (Figure 4C-F). In conclusion, our results suggest that the 
transcription factor FoxP1 is a direct target of miR-34a that is overexpressed in a majority of 
gDLBCL, but not in low grade lymphoma cases, and represents a bona fide oncoprotein in 
this disease entity.       
 
Our results thus establish a mechanistic link between over-expression of Myc, the 
concomitant repression of Myc-regulated miRNA genes, and the deregulation of FoxP1 (see 
schematic in Figure 5). Chromosomal translocations involving the MYC locus are reported in 
the literature for 50-60% of gDLBCL, but are never detected in gastric low grade lymphomas 
and rarely found in nodal DLBCL (Kramer et al., 1998; van Krieken et al., 1990). While 
chromosomal translocations involving the MYC locus are the likely cause for Myc 
overexpression in gDLBCL, other alternative mechanisms of Myc deregulation are 
conceivable. Myc is itself known to be post-transcriptionally regulated by miRNAs. 
Interestingly, several Myc-regulating miRNAs (including miR-34a and let7) are also targets 
of Myc repression, establishing a feedback loop that aggravates and perpetuates the effects of 
Myc overexpression and may thus contribute to cancer progression. Several lines of evidence 
argue that miR-34a is a strong tumor suppressor miRNA in solid cancers. It is located on 
chromosome 1p36.22 in a region that has previously been associated with various 
malignancies, including lung cancer (Calin et al., 2004b); it is transcriptionally induced by 
the tumor suppressor p53 and its overexpression inhibits growth of various cancer types in 
vitro (He et al., 2007). The first proof of principle for the success of miR-34a “replacement 
therapy” in cancer treatment was recently reported using a preclinical model of non-small 
cell lung cancer; the local and systemic delivery of chemically synthesized miR-34a was 
achieved in this model by formulation with a lipid-based delivery reagent (Wiggins et al., 
2010).  
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We demonstrate here for the first time that miR-34a has tumor suppressive properties 
in a hematopoietic malignancy. It is down-regulated in the malignant compared to the benign 
form of gastric lymphoma and its expression is directly regulated by Myc, which we show 
here to possess oncogenic properties in various DLBCL cell lines. Ectopic miR-34a re-
expression prevents DLBCL growth. Finally, we demonstrate that miR-34a targets a 
suspected hematopoietic oncogene in gastric lymphoma, FoxP1, which is over-expressed in 
the malignant form of gastric lymphoma and which possesses bona fide oncogenic properties 
in DLBCL. Our results confirm and extend previous reports describing FoxP1 
overexpression as a negative prognostic marker in gastric lymphoma and in nodal DLBCL 
(Hoeller et al; Sagaert et al., 2006). The post-transcriptional regulation of FoxP1 by miR-34a 
further provides a plausible explanation for the conundrum that FoxP1 is highly expressed in 
many lymphomas not harboring the rare chromosomal translocation t(3;14)(p13;q32), which 
juxtaposes the FOXP1 and IGH gene loci in certain non-gastric MALT lymphomas and 
extranodal DLBCL (Haralambieva et al., 2006; Streubel et al., 2005).  
 
 In conclusion, we postulate here that miR-34 replacement therapy should be 
considered not only for the treatment of solid cancers, but may also prove beneficial in 
patients with miR-34a-negative, FoxP1-overexpressing hematopoietic malignancies such as 
gastric DLBCL. The beneficial therapeutic effects of miR-34a are anticipated due to the 
strong tumor suppressive properties of this miRNA, which are exerted via its oncogene target 
FoxP1.   
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Materials and Methods  
 
Patient material and DLBCL cell lines 
For miRNA expression analysis of archived patient material, consecutive cases of H. 
pylori-positive gastritis, of H. pylori-positive gastric low grade MALT lymphoma, and of 
gastric high grade MALT lymphoma were drawn from the surgical pathology files of the 
Institute of Pathology at the Cantonal Hospital St. Gallen, Switzerland. All data were blinded 
to guarantee patients' protection. All procedures were in agreement with the guidelines for 
use of human material in research issued by the Hospital’s Ethics Committee. The DLBCL 
cell lines used were: two GC type (SUDHL4 and SUDHL6), one ABC type (U2932) and one 
unclassified DLBCL cell line (SUDHL7). All cell lines were maintained at 37 °C in RPMI 
1640 medium supplemented with 20% heat-inactivated fetal bovine serum and antibiotics. 
 
RNA extraction, microRNA expression profiling by microarray analysis and locked 
nucleic acid real time PCR for microRNA quantification 
Total RNA was extracted from three 20 μm slices per sample of formalin fixed, 
paraffin embedded material using the RecoverAll total RNA Isolation kit (Ambion, 
Streetsville, Canada). Total RNA concentrations were measured using an ND-1000 
spectrophotometer (NanoDrop Technologies). RNA integrity was confirmed on an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). All microarray 
experiments were performed using the Agilent Human miRNA Microarray Kit version 10.0. 
100 ng total RNA were hybridized per sample and processed according to the manufacturer’s 
instructions. The arrays were scanned with an Agilent Technology G2565B scanner. The 
scanned images were gridded and analyzed using Agilent Feature Extraction Software 
version 9.5. The 795 human mature miRNAs included on the array were represented by 2421 
probes; the average intensity of all probes corresponding to one miRNA was calculated. 
Normalization was performed using quantile normalization implemented in the bioconductor 
package PreprocessCore. The false discovery rate was computed using the Benjamini-
Hochberg algorithm. All raw data of the microarray experiments are publicly accessible 
(http://www.ncbi.nlm.nih.gov/geo/). The expression of mature miRNAs was analysed using 
the miRCURY locked nucleic acid (LNA) microRNA PCR system following the 
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manufacturer’s instructions (Exiqon, Vedbaek  
Denmark). Briefly, 10 ng of total RNA was subjected to cDNA synthesis using either 
miRNA- or U6 snRNA-specific primers. The cDNA template was diluted 1:10 and real time 
PCR reactions were performed following the manufactures’ recommendations (LightCycler; 
Roche, Basel, CH). Calculations of miRNA expression levels were performed using the 
comparative ΔΔCt method and normalized against U6 snRNA levels. 
 
Immunohistochemical staining and Western blotting  
The gastric lymphoma tissue microarray used in this study was constructed as 
described (Bernasconi et al., 2008) and included a total of 76 specimens, comprising 39 cases 
of gastric low grade MALT lymphomas and 37 cases of gastric DLBCL. The following 
primary antibodies were used: anti-MYC (N-262; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and anti-FOXP1 (ICI2; Abcam, Cambridge, MA, USA). MYC and FOXP1 levels 
were assessed by counting the number of positively staining tumour cells and graded using 
the following expression scale: a negligible level of staining of 0-10% was recorded as 
negative, while low expression was between 10-60% and high expression was recorded when 
60-100% tumour cells stained positive. Protein extracts were made using 2x Laemmli sample 
buffer (4% SDS, 20% glycerol, 120mM Tris [pH6.8]). Proteins were separated by 
SDS/polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. 
Membranes were probed with antibodies against FOXP1 (JC12; Abcam) or against α-tubulin 
(Santa Cruz Biotechnology) to control for equivalent gel loading.  
 
Cell lines, transfections and luciferase reporter assays 
On-target plus smartpool siRNAs for MYC, FOXP1 and a scrambled negative control 
was purchased from Dharmacon (Thermo Scientific, Lafayette, CO, USA). Precursor 
microRNA oligonucleotides (pre-miR-let-7a, pre-miR-34a, pre-miR-23a, pre-miR-26a, pre-
miR-150 and pre-miR-15) and scrambled negative control oligonucleotides were purchased 
from Ambion. For the purpose of siRNA or miRNA inrtoduction into DLBCL cells, 1x106 
cells were nucleoporated using an Amaxa Nucleoporator (Gaithersburg, MD, USA) with the 
specified amount of pre-miR miRNA precursor or siRNA. After 48 h, cells were harvested 
for RNA and protein analysis. After 72 h, tumor cell proliferation was quantified by [3H] 
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thymidine incorporation assay as previously described (Craig et al., 2010b). The pmirGLO 
Dual-Luciferase miRNA Target Expression Vector was purchased from Promega (Madison, 
WI, USA). HEK293T cells were seeded into 21-well plates at 1 x 105 cells/well 24 h before 
transfection. 1µg reporter plasmid containing the FOXP1 3’UTR or its mutants and 30nM 
mir-34a precursor molecules were contransfected into each well using the Fugene 6 
transfection reagent (Roche) in triplicates. Luciferase assays were performed 24 hr after 
transfection using the Dual-Luciferase Reporter Assay System (Promega) with a Spectramax 
M5 reader (Molecular Devices, Sunnyvale, CA, USA). 
 
Online supplemental material 
Two supplemental tables listing the differentially expressed miRNAs between 
gastritis and low grade lymphoma samples (suppl. Table 1) and between low grade and high 
grade lymphoma samples (suppl. Table 2) are available with the online version of this 
manuscript. (Two supplemental figures and the corresponding legends are included in the 
Figure legends and Figures sections of this manuscript.) 
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Figure 1. miRNA expression signatures of gastritis, low grade MALT lymphoma and 
gDLBCL.  (A) The expression of 795 human mature miRNAs included in version 10.0 of the 
miRBase database was analyzed for seven cases of gastritis, eight cases of low grade MALT 
lymphoma and seven gDLBCL cases using microarray technology. The result of 
unsupervised hierarchical clustering of all miRNAs that varied across the 22 arrays with a 
standard deviation of log2 expression >0.05 is shown in the heat diagram. All known Myc-
repressed miRNAs with lower expression in gDLBCL compared to low grade MALT 
lymphoma are annotated. (B,B) Quantification of let-7a (B) and miR-34a (C) expression in 
the samples shown in A by LNA real-time RT-PCR; absolute expression was normalized to 
U6 snRNA. 
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Figure 2. Myc is over-expressed in gastric diffuse large B-cell lymphoma (gDLBCL) 
and exhibits oncogenic properties in DLBCL cell lines in vitro. (A,B) Myc expression was 
analyzed by immunohistochemistry on a tissue microarray comprising 37 gDLBCL and 39 
low grade MALT lymphoma (MALT-L) cases. The fraction of MALT lymphoma and 
gDLBCL cases with high, low and no Myc expression is indicated in A; representative 
micrographs are shown in B. The scale bar indicates 50µm. (C,D) Quantification of let-7a 
(C) and miR-34a (C) expression as determined by LNA real-time RT-PCR for the indicated 
cells lines (U2932, SUDHL4) 48h after electroporation with Myc-specific or scrambled (NC) 
siRNA. Expression values were normalized to U6 snRNA levels. (E,F) Proliferation as 
assessed by [3H] thymidine incorporation of U2932 (E) and SUDHL-4 (F) cells 72 h after 
electroporation with Myc-specific or scrambled (NC) siRNA. (G,H) U2932 (G) and SUDHL-
4 (H) cells were electroporated with the indicated pre-miRs or scrambled negative control 
(NC) oligonucleotide 72 h prior to the quantification of proliferation by [3H] thymidine 
incorporation. 
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Figure 3. miR-34a directly targets FOXP1 in DLBCL. (A) U2932 cells were electro-
porated with pre-miR34a or a scrambled negative control pre-miR and analyzed with respect 
to FOXP1 expression 48 h later. FOXP1 transcript levels were normalized to GAPDH 
expression. (B) FoxP1 protein levels of the experiment described in A as analyzed by 
Western blot. α-tubulin levels are shown to control for equal loading. (C) Dual luciferase 
assay of HEK293T cells co-transfected with firefly luciferase constructs containing the wild-
type or mutant miR-34a (arrows represent mutations) target site of the FOXP1 3'UTR region 
downstream of the luciferase reporter. Cells were co-transfected with either pre-miR-34a or a 
negative control scrambled oligonucleotide and the respective luciferase construct. Data are 
represented as relative luciferase activity.  
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Figure 4. FOXP1 is a bone fide oncoprotein in DLBCL. (A,B) FoxP1 expression was 
analyzed by immunohistochemistry on the tissue microarray described in Figure 2. The 
fraction of MALT lymphoma and gDLBCL cases with high, low and no Myc expression is 
indicated in A; representative micrographs are shown in B. The scale bar indicates 50µm. (C-
F) U2932 (C), SUDHL4 (D), SUDHL6 (E) and SUDHL7 (F) cells were electroporated with 
pre-miR34a, a FoxP1-specific siRNA or the respective negative control (NC) scrambled 
oligonucleotides 72 h prior to the quantification of proliferation by [3H] thymidine 
incorporation. 
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Figure 5. Schematic representation of the interplay of Myc, miR-34a and FoxP1 during 
malignant transformation of low grade gastric MALT lymphoma to gDLBCL. Myc 
overexpression can be caused by chromosomal translocations involving Myc and Ig loci or 
other genetic abnormalities, or by post-transcriptional regulation through miRNAs such as 
members of the let7 family. Antigen dependence is lost during malignant transformation. 
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Suppl. Figure 1. The knock-down of Myc inhibits FoxP1 expression as efficiently as 
miR-34a introduction. U2932 cells were electroporated with either a Myc-specific siRNA, 
pre-miR34a or a scrambled negative control siRNA or pre-miR and analyzed with respect to 
FOXP1 expression 48 h later. FOXP1 transcript levels were normalized to GAPDH 
expression. 
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Suppl. Figure 2. siRNA-mediated FoxP1 knock-down reduced FoxP1 expression by 
64% on average. U2932, SUDHL4, SUDHL6 and SUDHL7 cells were electroporated with 
a FoxP1-specific siRNA or the respective negative control (NC) scrambled oligonucleotides 
72 h prior to the quantification of FoxP1 expression. 
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Suppl. Table 1:  List of differentially expressed miRNA genes between gastritis and low 
grade lymphoma samples with a p-value <0.05 and a fold-change >1.5.  
p-value: significance of differential expression between gastritis and MALT lymphoma 
samples as computed by t-test.  
Fold-change: absolute fold change calculated as the ratio of miRNA signal intensities in 
MALT lymphoma vs. gastritis.  
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Suppl. Table 2:  List of differentially expressed miRNA genes between low grade and 
high grade lymphoma samples with a p-value <0.05 and a fold-change >1.5.  
p-value: significance of differential expression between MALT lymphoma and high grade 
lymphoma samples as computed by t-test.  
Fold-change: absolute fold change calculated as the ratio of miRNA signal intensities in 
MALTL vs. high grade lymphoma.  
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4 DISCUSSION AND OUTLOOK 
 
MALT lymphoma attracts much attention owing to its unique clinical and molecular 
features and represents a paradigm for the study of inflammation-induced lymphomas. 
Despite keen interest in this disease, the molecular pathogenesis of MALT lymphoma has 
remained poorly understood. Research has been hindered by several limitations such as, the 
lack of an immortalised cell line in conjunction with the customary challenges involved in 
obtaining human patient material. The availability of a murine MALT lymphoma model 
coupled with our fortunate acquisition of rare human material gave us a unique standpoint to 
address several key unresolved issues concerning the molecular detail of MALT 
lymphomagenesis. This partly entailed revisiting familiar questions, namely concerning the 
role of infiltrating T cells and antigen-recognition, while on the on other hand, novel subject 
areas such as miRNA deregulation in tumourigenesis were also explored. The following 
sections discuss the main outcomes and impact of our research with a special focus on 
relevant future research prospects.  
  
4.1 Promiscuity is a pathogenic feature of MALT lymphoma  
 
Although multiple studies on MALT lymphoma have alluded to a role for antigen in 
the pathogenesis of this disease, the question has remained whether this interaction occurs 
directly via the surface Ig of the tumour B cells and if so, what are the exact ligands involved. 
Previously, the Ig of certain MALT lymphomas have been found to have a rheumatoid factor 
reactivity66 and binding of tumour Ig to various structures of normal human tissues (follicular 
dendritic cells, venules, epithelial cells, and connective tissue) has also been described.75, 172 
Our research on this ongoing theme of antigen specificity revealed that the tumour B cells 
behave in a polyspecific manner; not only did the recombinant MALT lymphoma-derived Igs 
exhibit broad reactivity against a panel of diverse antigens in a series of enzyme 
immunoassays, but we were further able to demonstrate in an ex vivo setting that murine 
tumour cells proliferate in response to the same panel of cognate antigens. Our experimental 
finding of polyreactivity was further supported by molecular analysis of MALT lymphoma 
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Igs, wherein many of the known hallmarks of polyreactive antibodies such as IgM class, a 
longer than average CDR3 length and restricted VH gene usage were detected.  
 
Overall, our results suggest that the development of MALT lymphoma may be 
facilitated by an array of local self- and foreign antigens, providing direct antigenic 
stimulation of the tumour cells via their BCR. In a broad sense, our findings provide 
experimental support for the expanding ideology that antigen-stimulation via the BCR is an 
important pathogenic feature of many B-cell lymphomas, such as follicular lymphoma173-
175and Burkitt’s lymphoma.174, 176-178 The phenomenon of polyreactivity is a well known 
concept among B cells, with a major proportion of the natural antibody repertoire consisting 
of polyspecific antibodies.179 Despite their preponderance, little experimental data exists 
concerning their biological function; however, it is currently assumed that they may play a 
role in the development and maintenance of immunological tolerance. The general 
mechanism to explain multispecific ligand recognition by antibodies is that the antigen-
binding pocket possesses a degree of conformational flexibility thereby, permitting the 
receptor to engage multiple ligands.179, 180 
 
In connection to other B-cell malignancies, polyreactivity is not a unique feature of 
MALT lymphoma. Chronic lymphocytic leukaemia (CLL) is the most prevalent form of 
adult leukaemia in the Western world181 and like MALT lymphoma, it is considered to be an 
antigen-driven neoplasm. Several studies have noted that tumour cells with a polyreactive 
binding capacity distinguish CLL cases with a worse clinical prognosis from those with 
better outcomes.182-184 In contrast to MALT lymphoma, most polyreactive CLL cells have not 
undergone somatic hypermutation, rather IgV sequence analysis suggests that the CLL clones 
have undergone various types of receptor editing.185-187 In receptor editing, antigen encounter 
induces autoreactive B cells to undergo secondary rearrangements of the light chain to 
augment their specificity from self to non-self. 
 
The persistence of polyreactivity, particularly in the face of receptor configuration, is 
somewhat paradoxical since the immune system is ostensibly programmed to delete such 
inappropriate and deleterious antigen reactivity. Remarkably, we found that the only 
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recombinant MALT lymphoma-derived Ig that failed to exhibit polyreactivity was also the 
only unmutated antibody among those analysed. Of future interest would be to determine if 
the link between mutation status and polyreactive binding profile remains consistent in larger 
studies that include more of the rare unmutated cases. One way we have began to elucidate 
the role of somatic hypermutation in MALT lymphoma development is by experimental 
infection of activation-induced cytidine deaminase (AID)-knock out mice with H. felis. The 
enzyme, AID, is known to be essential to both somatic hypermutation and class switch 
recombination of Ig188, 189 and is highly expressed in a variety of B-cell neoplasms, including 
MALT lymphoma.190-193 We observed that only one out of the seven infected AID-/- mice 
actually developed lymphomas after 18 months of infection, while the remaining animals 
were tumour-free (data not shown). These preliminary data therefore support the notion that 
AID-mediated antigen-receptor gene modification processes may be a principal contributor 
to the pathogenesis of MALT lymphoma. 
 
In light of the simultaneous occurrence of polyreactivity and receptor configuration, a 
recent investigation demonstrated that pathogenic polyreactive antibodies have undergone a 
higher rate of somatic hypermutation compared with pathogenic monoreactive 
autoantibodies.194 Furthermore, many investigators have now demonstrated that lupus-
inducing autoantibodies tend to be polyreactive or cross-reactive rather than 
monospecific.195-197 These results support the recent paradigm shift that polyreactive 
autoantibodies are more pathogenic than monoreactive autoantibodies. In this context, 
polyreactivity certainly lends well to the hypothesis that B cells with a promiscuous antigen 
receptor have a higher risk of accruing genetic lesions and undergoing subsequent malignant 
transformation due to the sheer availability of cognate antigen that may trigger rapid cell 
divisions. It is therefore tempting to speculate that a polyreactive BCR may provide an 
important growth advantage for the neoplastic B-cell clone at an early stage; as transforming 
events accumulate, dependence on the presence of the BCR may be lost symbolising the 
evolution of MALT lymphoma into aggressive gDLBCL. The fact that some gDLBCLs have 
regressed upon eradication of H. pylori, suggests that these lymphomas may have preserved 
their antigen dependence and thus lures us to consider the BCR as an integral pathogenic 
feature of these lymphomas. Further research is required to determine the proportion of 
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gDLBCLs that are sensitive to eradication therapy and whether these tumour cells behave in 
a polyspecific manner.  
 
4.2  Tumour-infiltrating T cells are essential for MALT lymphoma    
 
The discovery of a large infiltrating CD4+ T-cell population in the MALT lymphoma 
environment triggered an exciting cascade of research aimed at characterising and 
understanding the significance of this populace (see section 1.1.4.2). Tumour-infiltrating 
CD4+ T cells are known to co-express CD40L and the activation marker CD69 and strongly 
produce Th2 cytokines such as IL4.11, 198 Several groups have reported that tumour-
infiltrating T cells are specific for H. pylori, and have postulated that T cells rather than 
tumour B cells constitute the Helicobacter-specific component of the tumour mass.32, 199 
Finally, an important finding by Greiner et al.63 was that MALT lymphoma cells are 
stimulated to proliferate in the ‘CD40 culture system’, that is, under constant stimulation 
with an agonistic CD40 antibody in conjunction with Th2 cytokines. This observation led to 
the conclusion that CD40 signalling was essential for tumour B-cell proliferation.63 
 
We set out to further examine the influence of T cells in the evolution of MALT 
lymphoma. To this end we established transient ex vivo cultures of murine MALT lymphoma 
cells and found, using this model system, that systemic depletion of all CD4+ or CD40L+ 
cells from the cultures largely abrogated tumour cell proliferation; the depletion of CD25+ T 
cells had a slightly weaker, but nevertheless significant effect. We conclude that these T cells 
are essential for providing B-cell stimulatory signals. Unexpectedly however, blocking the 
direct interaction between CD40L and its receptor failed to quell tumour cell proliferation. 
Our data therefore suggests that tumour cell proliferation is enhanced by the presence of 
intratumoural CD4+ T cells in a CD40/CD40L-independent manner. Our data confirm 
previous results by Greiner et al.200 who also reported CD40L expression on human MALT 
lymphoma infiltrating T cells. However, our results challenge the dogma that tumour B cells 
rely on direct contact with T cells via CD40 signalling. Although the tumour B cells can in 
principle respond to agonistic CD40 stimulation due to high CD40 expression, the direct 
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interaction between the B and T cells through CD40/CD40L appears not to be essential for 
tumour cell proliferation, at least in an ex vivo setting.  
 
Our research lays a fertile groundwork for future efforts aimed at delineating the 
soluble activated T cell-derived factors or potential non-CD40-mediated contact dependent 
mechanisms driving the proliferation of the tumour cells. Prospective studies should foremost 
include the manipulation of the Th2 cytokine profile of the MALT lymphoma environment to 
identify the chief soluble tumour-promoting mediators. In regards to alternative contact 
dependent mechanisms, the CD28/CTLA4 ligand CD86 represents a key suspect worthy of 
investigation; CD86 is expressed on MALT lymphoma cells58-60 and evidence has surfaced 
that this costimulatory molecule may promote T-cell mediated neoplastic B-cell growth.201  
 
An unprecedented finding of our study was the high concentration of FoxP3+ Treg 
cells within the tumour-infiltrating T-cell compartment, both in the murine tumours and in 
human patient biopsy material. Tregs are known to protect the host from autoimmune disease 
and mediate peripheral tolerance by suppressing autoreactive immune cells.202 Moreover, it is 
becoming increasingly clear that Tregs are also involved in fostering an immune-privileged 
niche and blocking antitumour immunity.203-205 Consistent with this concept, is the 
overrepresentation of Treg cells reported in various types of cancer.203, 205-211 In our model of 
Helicobacter infection-induced MALT lymphoma, monoclonal antibody-mediated depletion 
of CD25+ Treg cells reduced the tumour burden as efficiently as the depletion of all CD4+ T 
cells, presumably by inducing the regression of pre-existing tumours. This finding is 
supported by the equally robust effect of Treg depletion on tumour cell proliferation 
observed ex vivo.  
 
Several animal tumour models have demonstrated improved tumour immunity and 
tumour regression upon in vivo administration of a CD25-specific antibody.212-215 Given that 
CD25-specific antibody treatment has been proven to efficiently deplete Treg cells, enhance 
tumour immunity and result in mouse tumour regression, reducing the Treg content of cancer 
patients may be of therapeutic value. However, conjecture surrounds the ability of CD25 
depletion to specifically eliminate Tregs in the tumour microenvironment, since CD25 is also 
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expressed on the cell surface of activated T cells.216 In spite of this, CD25 depletion has been 
shown not to result in elimination of effector T cells, but rather to significantly enhance 
activated T-cell numbers.217 Furthermore, CD25-directed Treg depletion has proceeded to 
clinical application and shown to decrease the number of CD4+ CD25+ FOXP3+ Treg cells 
while heightening antitumour T-cell responses as measured in the blood of patients with 
renal cell carcinoma and metastatic melanoma.218, 219 Although depletion of Treg cells is an 
attractive option, careful clinical studies are needed with large patient populations to link 
Treg depletion with potential clinical efficacy.  
 
The observation that Tregs are overrepresented in the MALT lymphoma environment 
raised the question of whether these cells were actively recruited to the tumour site. Our 
results provide evidence that the malignant B cells are involved in the chemotaxis of 
intratumoural Treg by secretion of two chemokines CCL17 (also known as thymus and 
activation-related chemokine, TARC) and CCL22. These chemokines, either alone or in 
combination, had previously been shown to recruit Tregs into epithelial cancers of the 
stomach220 and ovaries.205 Notably, Curiel et al.205 demonstrated that an in vivo blockade of 
CCL22 significantly reduced Treg migration to the tumour site. These reports therefore 
suggest that in addition to depleting Tregs, targeting the molecules involved in Treg-cell 
tumour trafficking represents an alternative strategy for controlling Treg function. 
 
Finally, we have shown that the intratumoural Tregs in MALT lymphoma specimens 
are highly suppressive against autologous effector T cells, more so than natural CD25+ Tregs 
isolated from the corresponding spleens and mesenteric lymph nodes of the same mouse. 
Although our results collectively indicate an important role for Treg cells in the regulation of 
MALT lymphoma growth, it remains uncertain if the suppressive activity of intratumoural 
Tregs is required for their tumour-promoting function. In dispute of the notion that malignant 
B cells benefit from intratumoural Tregs through mechanisms of immune privilege, we 
alternatively propose the concept that low grade MALT lymphomas may be directly 
stimulated by Treg-derived contact-dependent or soluble signals. Our first line of evidence 
stems from the observation that Treg depletion inhibits tumour B-cell proliferation in vitro, 
an effect unlikely due to enhanced antitumour immune responses. Secondly, low grade 
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MALT lymphoma harbours more Tregs and overall infiltrating T cells than their transformed 
autonomously growing gDLBCL counterpart.  
 
Our data is similar to previous findings in other non-Hodgkin’s lymphoma, where an 
increased percentage of FOXP3+ Treg cells is predictive of better prognoses.221-223 In 
particular, Carreras et al.221 reported a marked decrease in the number of Tregs during the 
transformation of follicular lymphoma to DLBCL, suggesting that these cells may play a role 
in tumour progression. The authors proposed that Tregs may facilitate lymphoma progression 
due to their inhibitory effects on the tumour B cells. This notion is supported by reports that 
Tregs are capable of directly suppressing B cells by inhibiting Ig production224 or by 
inducing cell death mediated by a cytotoxic-dependent pathway.225 By way of contrast, a 
high Treg frequency appears to closely correlate with poor prognoses and reduced survival 
rates for many other types of cancers.205, 207-209 In this setting, high numbers of Tregs are 
thought to benefit the tumours by blocking antitumour immune responses, thereby fostering 
an immune privileged tumour microenvironment.  
 
We conclude from our results that MALT lymphomas are infiltrated by Tregs that are 
highly suppressive towards effector T cells on one hand, and essential for optimal tumour B-
cell proliferation on the other. Future research is warranted to elucidate the mechanisms 
through which Tregs promote tumour B-cell proliferation in the ex vivo culture model we 
have established; for example, the neutralisation of soluble or contact-dependent Treg-
derived markers such as IL10, TGFβ and CTLA4 should clarify whether these signals are 
crucial for promoting tumour cell proliferation ex vivo. Taken together, we provide strong 
evidence that both antigen stimulation and infiltrating T cells may synergistically contribute 
to the development of MALT lymphoma during persistent H. pylori infection (Figure 4.1).  
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Figure 4.1 B-cell receptor signalling and CD40 ligand-independent T-cell help cooperate to drive MALT 
lymphoma cell proliferation. Tumour B cells proliferate in response to a variety of antigenic stimuli via a 
polyreactive B-cell receptor (BCR). In parallel, tumour-infiltrating T-helper type 2 (Th2) and functional 
regulatory T cells (Tregs) provide signals required for the proliferation and survival of MALT lymphoma B 
cells. The tumour cells actively recruit the tumour cells through secretion of the Treg-attracting chemokines 
CCL17 and CCL22 which bind to a shared receptor on the Treg surface, CCR4.  
 
 
 
4.3  MicroRNA deregulation: a novel player in the development and 
progression of MALT lymphoma 
 
4.3.1 miR-203 controls the oncogene ABL1 in MALT lymphoma with 
therapeutic consequences 
 
A large body of evidence has documented the influence of miRNAs in 
tumourigenesis. However, the contribution of miRNA to the pathogenesis of MALT 
lymphoma has remained in the dark. To shed light on this subject, we used a genome-wide 
microarray approach to identify miRNAs potentially involved in the various stages of MALT 
lymphomagenesis. As expected, the miRNA expression signature of MALT lymphoma was 
more closely related to gastritis than to gDLBCL. This observation clearly reflects the 
biological similarities shared between the former two disease entities compared to the latter 
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more aggressive tumour counterpart. Nevertheless, the molecular events that drive the 
transition from reactive H. pylori-dependent gastritis to MALT lymphoma are poorly 
demarcated.  
 
Our microarray-based miRNA transcriptome analysis identified miR-203 as one of the most 
strongly downregulated miRNAs in gastric lymphoma. We verified that miR-203 was indeed 
significantly downregulated in MALT lymphoma compared to gastritis and normal tonsil 
tissue using real-time PCR. Silencing of the miR-203 gene locus in both low and high grade 
MALT lymphoma was found to be due to extensive promoter CpG hypermethylation. 
Several lines of evidence support a tumour suppressive role for miR-203 in MALT 
lymphoma. Its expression is downregulated in cancers of the liver,226 central nervous 
system,227 esophagus,228 and in certain types of leukaemia.229 Experimental inhibition of 
miR-203 using an antisense approach was shown to enhance the growth of lung carcinoma 
cell lines.230 Conversely, the restoration of miR-203 expression significantly reduced cellular 
proliferation of hepatocellular carcinoma,231 types of leukaemia such as chronic myelogenous 
leukaemia (CML)229 and head and neck squamous cell carcinoma.232 Finally, an 
experimentally validated target of miR-203 is the ABL1 non-receptor tyrosine kinase proto-
oncogene.229 
 
The oncogenic role of ABL1 has been extensively characterised in human leukaemias 
that harbour the t(9;22) reciprocal translocation fusing the BCR and ABL1 gene loci, known 
as the Philadelphia chromosome (Ph). This translocation is a hallmark of CML and is also 
present in a fraction of B-cell acute lymphoblastic leukaemias (ALL) that have a particularly 
poor prognosis.233 Although MALT lymphomas are Ph-negative, we found that ABL1 is 
overexpressed in both human and murine MALT lymphoma samples in comparison to 
corresponding gastritis material. Our findings are in line with the recent observations that 
ABL1 is de-regulated in a variety of Ph-negative malignancies, such as CLL,79, 234, 235 
breast,236 thyroid237 and lung cancer.238  
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The ABL1 protein is ubiquitously expressed and localised both in the nucleus and 
cytoplasm where it is involved in diverse processes such as, the regulation of cell growth, 
survival, proliferation, migration and cellular responses to DNA damage and oxidative 
stress.239 Although ABL1 is expressed in all mammalian tissues, its levels are highest in the 
thymus, spleen, and testes.240 It is clear that ABL1 expression is crucial for normal B-cell 
development, as mice homozygous for a mutation in the ABL1 gene have multiple defects 
including high postnatal mortality, thymic and splenic atrophy and a T- and B-cell 
lymphopenia.240 ABL1 is thought to regulate B-cell proliferation downstream of the BCR, 
possibly by directly interacting with, and phosphorylating, the BCR co-receptor CD19.241 B 
cells derived from ABL1-/- mice exhibit an impaired proliferative response following BCR 
engagement.241 In addition, levels of ABL1 are elevated in the cytosol following BCR 
engagement in the B-cell lines Raji and Ramos.241 Consistent with its involvement in BCR 
signalling, ABL1 is believed to play a pathogenic role in CLL cells through a mechanism 
involving constitutive NF-κB activation.234 Aberrant NF-κB signalling is a hallmark of 
MALT lymphoma. Thus deregulated ABL1 expression points to a possible mechanism for 
uncontrolled NF-κB activation in MALT lymphoma. Despite these emergent clues, the 
precise oncogenic action of ABL1 in MALT lymphoma awaits confirmation and points to an 
exciting area of future research.  
 
Given that ABL1 is implicated in the dysregulation of the NF-κB pathway via BCR 
signalling and is overexpressed in MALT lymphoma we hypothesised that ABL1 inhibition, 
either by miR-203 re-expression or inhibition of ABL1’s tyrosine kinase activity would block 
the Helicobacter-induced proliferation of primary MALT lymphoma cells. Indeed, both 
lentiviral delivery of miR-203 and treatment of explanted murine MALT lymphoma cells 
with the tyrosine kinase inhibitor imatinib efficiently prevented their proliferation. 
Administration of chronically Helicobacter-infected mice with imatinib, prevented MALT 
lymphomagenesis, suggesting that ABL1 inhibition may be a valid strategy for the treatment 
of patients that are refractory to eradication therapy. Indeed the therapeutic effect of imatinib 
in MALT lymphoma probably reflects the critical role of antigen-induced signalling from the 
BCR in the pathogenesis of the tumour.  
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As well as being the current first-line therapy for CML, imatinib has been approved 
for the treatment of chronic eosinophilic leukaemia, gastrointestinal stromal tumours and Ph-
positive ALL (Ph-positive).233, 242 In addition, pre-clinical studies recommend imatinib for 
the treatment of CLL patients overexpressing ABL1.79, 234 Given our results, it is worthwhile 
to consider the potential benefit of imatinib treatment for gDLBCL which, in resemblance its 
low grade counterpart, is miR-203 deficient. However, the question remains open whether 
gDLBCLs also overexpress ABL1, thereby rendering the lymphoma sensitive to imatinib 
treatment. We therefore await the opportunity to treat ABL1-postive, miR-203-negative 
DLBCL cells with imatinib.  
 
In conclusion, (as summarised in Figure 4.3) we propose that the evolution of 
Helicobacter-associated gastritis to low grade MALT lymphoma may be epigenetically 
regulated through hypermethylation of the miR-203 promoter; the subsequent silencing of 
miR-203 expression results in deregulation of ABL1, which in turn drives MALT lymphoma 
cell proliferation. Our results identify ABL1 as a promising new target for the treatment of 
MALT lymphoma; in particular, the pharmacological inhibition of this kinase may be of 
therapeutic benefit to patients who are refractory to antibiotic eradication therapy.  
 
 
 
 
Figure 4.3  Model of ABL1 
regulation by miR-203 in MALT 
lymphoma. MiR-203 is specifically 
epigenetically silenced in MALT 
lymphoma compared to non-tumour 
tissue. The miR-203 promoter is 
embedded in a CpG island which 
remains unmethylated in gastritis but 
is hypermethylated in MALT 
lymphoma. The loss of miR-203 leads 
to upregulation of ABL1 expression 
which contributes to uncontrolled 
proliferation of the neoplastic B cells. 
Open circles depict unmethylated 
CpG sites and the filled circles 
represent methylated CpG sites 
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4.3.2 MYC-mediated repression of miR-34a promotes high grade 
transformation of MALT lymphoma through its target FOXP1  
 
To elucidate the biological mechanisms underlying the event of MALT lymphoma 
transformation into gDLBCL we compared the miRNome of low and high grade MALT 
lymphoma samples. Of the large number of miRNAs differentially expressed between these 
two disease entities, the vast majority were downregulated in the gDLBCL cases analysed. 
Global reduction of miRNA expression is a hallmark of cancer progression and is thought to 
contribute to neoplastic transformation by allowing an increased expression of 
oncoproteins.164 Interestingly, the transcription factor MYC is known to directly suppress the 
expression of a large number of human miRNAs, thereby contributing to the phenomenon of 
reduced abundance of select miRNAs in cancer cells.162, 163, 243 Moreover, many of these 
MYC-associated miRNAs have known tumour suppressive activity thereby strengthening the 
tumour promoting program of MYC.  
 
Remarkably, the majority of known MYC-repressed miRNAs were found to be 
significantly downregulated in the transformed high grade, but not the low grade cases of 
MALT lymphoma analysed. This implies that MYC may dramatically influence the miRNA 
expression profile of gDLBCL. To test this hypothesis, we compared MYC expression levels 
between cases of low and high grade MALT lymphoma using a tissue microarray platform 
and demonstrated that aberrant MYC expression is strongly associated with gDLBCL. This 
correlation is not entirely surprising since the presence of MYC rearrangements are often 
detected in gDLBCL patients, while rarely being found in low grade MALT lymphoma and 
nodal DLBCL.105, 107 An alternative source for MYC overexpression is based on evidence 
that MYC itself is post-transcriptionally regulated by certain MYC-repressed miRNAs thus 
establishing a feedback loop that exacerbates and strengthens the oncogenic effects of 
MYC.162, 244 For instance, in Burkitt’s lymphoma translocation of the MYC gene is generally 
considered a hallmark of this disease; however, a very small number of cases do not exhibit 
any MYC gene rearrangements, yet still overexpress MYC.244 In these translocation-negative 
Burkitt’s lymphoma cases, suppression of the miRNAs let-7c and miR-34b (which negatively 
regulate MYC) has been put forward as the probable cause of MYC overexpression.244 
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To assess the causal link between aberrant MYC expression and miRNA 
downregulation in gDLBCL, we transiently knocked down MYC by siRNA in DLBCL cell 
lines. Upon MYC silencing, we confirmed the concomitant upregulation of known MYC-
repressed miRNAs, let-7 and miR-34a. In addition, the growth of the tumour cells was 
significantly blocked bolstering the notion that MYC expression drives DLBCL proliferation, 
possibly via downregulation of tumour suppressive miRNAs. To explore the potential tumour 
suppressive impact of MYC-repressed miRNAs in lymphomagenesis, we re-expressed a 
panel of these miRNAs in DLBCL cell lines. Although all six of the miRNAs that were 
examined significantly reduced the proliferation of the tumour cells, the restoration of miR-
34a levels had the most potent effect on tumour cell proliferation. Ectopic expression of miR-
34a has also been found to display an anti-proliferative phenotype in several solid tumour 
cell lines.245-249 A recent breakthrough concerning miR-34a was the demonstration of lung 
tumour growth inhibition in mice following systemic delivery of miR-34a oligonucleotide 
mimics.260 Enforced expression of miR-34a may therefore hold significant promise as a 
novel therapeutic modality for human gDLBCL. 
 
In support of its role as a tumour suppressor, miR-34a has been shown to regulate 
genes involved in apoptosis, cell growth and cell-cycle regulation, including MYCN, BCL2 
and CDK6.145, 250, 251 The anti-oncogenic nature of miR-34a is reinforced by the finding that it 
is transcriptionally induced by the TP53 tumour suppressor.252 To further investigate the anti-
tumourigenic action of miR-34a we and others have extended the list of its direct targets to 
include the forkhead transcription factor FOXP1.253 In addition, we found using our tissue 
microarray platform that high FOXP1 expression strongly correlates with gDLBCL. Recent 
attention has focused on FOXP1 and its role in tumourigenesis due to its upregulation in a 
variety of B-cell neoplasias. In particular, Sagaert et al.112 found FOXP1 positive MALT 
lymphomas to be at an increased risk of transforming into aggressive DLBCLs. Likewise, 
overexpression of FOXP1 in a subset of DLBCL indicates poor prognosis.111, 112, 254, 255 The 
primary means responsible for FOXP1 deregulation has remained contentious due to the 
seldom occurrence of FOXP1 gene rearrangements in FOXP1-positive lymphomas.111, 256 As 
such, post-transcriptional regulation of FOXP1 by miR-34a is a conceivable alternative 
mechanism underlying the frequent deregulation of the transcription factor in lymphomas.   
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 While the correlation data argue for FOXP1 having a possible role in the 
pathogenesis of DLBCL, experimental data is lacking to support a tumour promoting 
function. To address this issue we transiently knocked down FOXP1 activity by siRNA in 
DLBCL cell lines in order to monitor the effect on proliferation status. Indeed, the 
knockdown of FOXP1 recapitulated the blocked proliferation phenotype of DLBCL cells 
observed by enforced expression of miR-34a. The beneficial therapeutic effects of miR-34a 
are therefore anticipated due to its potent tumour suppressive properties exerted via the 
FOXP1 oncoprotein. Of future interest is to define the precise mechanism of FOXP1 activity 
in the context of haematological malignancies. At present, FOXP1 is known to be an 
essential regulator of normal early B-cell development and regulates immunoglobulin 
rearrangements by controlling the expression of both RAG1 and RAG2 genes.109 As yet there 
have been no comprehensive studies to identify additional FOXP1 target genes which may 
aid in uncovering how this transcriptional repressor contributes to lymphomagenesis. Taken 
together, our results indicate that FOXP1 is frequently overexpressed in gDLBCL, is a direct 
target of MYC-dependent miR-34a, and represents a bona fide oncoprotein in this disease 
entity (Figure 4.2). We further propose miR-34a as a potential therapeutic target in the 
treatment of miR-34a-deficient, FOXP1-overexpressing lymphomas such as gDLBCL.  
 
 
 
Figure 4.2  Hypothetical model of 
the progression of MALT 
lymphoma to gastric diffuse large 
B-cell lymphoma (gDLBCL). 
Aberrant expression of MYC can be 
caused by genetic abnormalities or 
by post-transcriptional regulation 
through miRNAs, such as let-7 
family members. MYC 
overexpression and the resultant 
repression of miR-34a leads to 
FOXP1 deregulation and ultimate 
high grade transformation into 
gDLBCL as evidenced by loss of 
antigen dependence.    
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Gastric DLBCL is an aggressive fast-growing disease with inferior survival rates 
compared to MALT lymphoma. The addition of a chimeric anti-CD20 monoclonal antibody, 
rituximab, in combination with standard CHOP treatment has been shown to significantly 
increase survival in DLBCL patients.257, 258 Despite this progress, there is a clear need for the 
development of more effective therapeutic strategies in order to improve the outlook for 
patients who have undergone transformation to DLBCL. Therapeutic strategies based on 
miRNA have added a new dimension to the treatment of cancer. miRNA replacement therapy 
is based on the concept of reintroducing a depleted, naturally occurring, tumour suppressive 
miRNA into cancer cells in order to suppress proliferation. In this regard, miRNA 
replacement therapy aims to restore a loss of function in tumour cells, unlike the inhibitory 
approach of other therapeutic modalities such as kinase inhibitors and siRNA. In a recent 
breakthrough study, Mendell and colleagues demonstrated in a mouse model of 
hepatocellular carcinoma that viral-mediated systemic delivery of a single miRNA, miR-26a, 
reversed disease progression without toxicity.259 Most recently, the group of Bader used a 
non-viral lipid-based approach to systemically deliver synthetic miR-34a to block tumour 
growth in a mouse model of lung cancer.260 In both studies, the treatment was well-tolerated, 
highly tumour specific and did not induce an immune response.  
 
Together these findings provide proof-of-concept support for the systemic delivery of 
anti-tumourigenic miRNAs as a powerful therapeutic approach. Although the in vivo 
potential of miRNA replacement therapy has not yet been explored in the context of 
heamatopoietic cancers, manipulating miR-34a levels to suppress tumour cell proliferation 
presents an exciting and promising approach for the treatment of DLBCL. It should also be 
noted, that other types of lymphomas, such as CLL261 and Burkitt’s lymphoma,262 are miR-
34a deficient. This strengthens the rationale for exploring the therapeutic potential of miR-
34a in malignancies beyond solid tumours. In particular, Burkitt’s lymphoma, represents an 
ideal model to investigate the potential benefit of miR-34a replacement in MYC 
overexpressing lymphomas. The challenge of in vivo delivery to effectively target tumour B 
cells will be the chief focus of future therapeutic development efforts to harness the full 
potential of miR-34a as a tumour suppressor agent.  
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Taken together, our findings provide novel insights into the molecular detail of the 
complex biological mechanisms underpinning the unique pathogenesis of MALT lymphoma. 
Our studies reinforce this disease entity as an excellent model to study how antigenic drive, 
microenvironmental stimuli and epigenetic deregulation coalesce to promote 
lymphomagenesis and ultimately pave the way for the development and design of rational 
therapeutic modalities.  
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